<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">16078</article-id><article-id pub-id-type="doi">10.7554/eLife.16078</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Human Biology and Medicine</subject></subj-group></article-categories><title-group><article-title>Homozygous <italic>YME1L1</italic> mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-55556"><name><surname>Hartmann</surname><given-names>Bianca</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-55557"><name><surname>Wai</surname><given-names>Timothy</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="equal-contrib">†</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa1">‡</xref></contrib><contrib contrib-type="author" id="author-55558"><name><surname>Hu</surname><given-names>Hao</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/><xref ref-type="fn" rid="pa2">§</xref><xref ref-type="other" rid="data-ro1"/></contrib><contrib contrib-type="author" id="author-62237"><name><surname>MacVicar</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55559"><name><surname>Musante</surname><given-names>Luciana</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55560"><name><surname>Fischer-Zirnsak</surname><given-names>Björn</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55561"><name><surname>Stenzel</surname><given-names>Werner</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55562"><name><surname>Gräf</surname><given-names>Ralph</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55563"><name><surname>van den Heuvel</surname><given-names>Lambert</given-names></name><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55564"><name><surname>Ropers</surname><given-names>Hans-Hilger</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-55565"><name><surname>Wienker</surname><given-names>Thomas F</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-63637"><name><surname>Hübner</surname><given-names>Christoph</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-3349"><name><surname>Langer</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-53521"><name><surname>Kaindl</surname><given-names>Angela M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9454-206X</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-9"/><xref ref-type="other" rid="par-10"/><xref ref-type="other" rid="par-11"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Institute of Cell Biology and Neurobiology</institution>, <institution>Charité University Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><label>2</label><institution content-type="dept">Department of Pediatric Neurology</institution>, <institution>Charité University Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Sozialpädiatrisches Zentrum (SPZ), Center for Chronically Sick Children</institution>, <institution>Charité University Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff4"><label>4</label><institution>Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff><aff id="aff5"><label>5</label><institution>Max Planck Institute for Molecular Genetics</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff6"><label>6</label><institution>Guangzhou Women and Children's Medical Center</institution>, <addr-line><named-content content-type="city">Guangzhou</named-content></addr-line>, <country>China</country></aff><aff id="aff7"><label>7</label><institution content-type="dept">Institut of Medical Genetics and Human Genetics</institution>, <institution>Charité University Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff8"><label>8</label><institution content-type="dept">Institute of Neuropathology</institution>, <institution>Charité University Medicine</institution>, <addr-line><named-content content-type="city">Berlin</named-content></addr-line>, <country>Germany</country></aff><aff id="aff9"><label>9</label><institution content-type="dept">Department of Cell Biology</institution>, <institution>University of Potsdam</institution>, <addr-line><named-content content-type="city">Potsdam</named-content></addr-line>, <country>Germany</country></aff><aff id="aff10"><label>10</label><institution content-type="dept">Nijmegen Center for Mitochondrial Disorders</institution>, <institution>Radboud University Medical Center</institution>, <addr-line><named-content content-type="city">Nijmegen</named-content></addr-line>, <country>Netherlands</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Gleeson</surname><given-names>Joseph G</given-names></name><role>Reviewing editor</role><aff id="aff11"><institution>Howard Hughes Medical Institute, The Rockefeller University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>angela.kaindl@charite.de</email></corresp><fn fn-type="present-address" id="pa1"><label>‡</label><p>Institut Necker Enfants Malades, INSERM U1151, CNRS UMR 8253, University Paris Descartes, Paris, France</p></fn><fn fn-type="present-address" id="pa2"><label>§</label><p>Guangzhou Women and Children’s Medical Center, Guangzhou, China</p></fn><fn fn-type="con" id="equal-contrib"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="pub" publication-format="electronic"><day>06</day><month>08</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e16078</elocation-id><history><date date-type="received"><day>24</day><month>03</month><year>2016</year></date><date date-type="accepted"><day>28</day><month>07</month><year>2016</year></date></history><permissions><copyright-statement>© 2016, Hartmann et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Hartmann et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-16078-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.16078.001</object-id><p>Mitochondriopathies often present clinically as multisystemic disorders of primarily high-energy consuming organs. Assembly, turnover, and surveillance of mitochondrial proteins are essential for mitochondrial function and a key task of AAA family members of metalloproteases. We identified a homozygous mutation in the nuclear encoded mitochondrial escape 1-like 1 gene <italic>YME1L1</italic>, member of the AAA protease family, as a cause of a novel mitochondriopathy in a consanguineous pedigree of Saudi Arabian descent. The homozygous missense mutation, located in a highly conserved region in the mitochondrial pre-sequence, inhibits cleavage of YME1L1 by the mitochondrial processing peptidase, which culminates in the rapid degradation of YME1L1 precursor protein. Impaired YME1L1 function causes a proliferation defect and mitochondrial network fragmentation due to abnormal processing of OPA1. Our results identify mutations in <italic>YME1L1</italic> as a cause of a mitochondriopathy with optic nerve atrophy highlighting the importance of YME1L1 for mitochondrial functionality in humans.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.001">http://dx.doi.org/10.7554/eLife.16078.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>YME1L1</kwd><kwd>mitochondriopathy</kwd><kwd>intellectual disability</kwd><kwd>optic atrophy</kwd><kwd>OPA1</kwd><kwd>mitochondrial fragmentation</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100010121</institution-id><institution>Sonnenfeld Stiftung</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hartmann</surname><given-names>Bianca</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution>Deutsche Gesellschaft für Muskelkranke e.V.</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hartmann</surname><given-names>Bianca</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004412</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Wai</surname><given-names>Timothy</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004189</institution-id><institution>Max-Planck-Gesellschaft</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Hu</surname><given-names>Hao</given-names></name><name><surname>Musante</surname><given-names>Luciana</given-names></name><name><surname>Ropers</surname><given-names>Hans-Hilger</given-names></name><name><surname>Wienker</surname><given-names>Thomas F</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>KO2891/1-1</award-id><principal-award-recipient><name><surname>Fischer-Zirnsak</surname><given-names>Björn</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000097</institution-id><institution>National Center for Research Resources</institution></institution-wrap></funding-source><award-id>P20 RR016453</award-id><principal-award-recipient><name><surname>Ropers</surname><given-names>Hans-Hilger</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>EU FP 7 project GENCODYS</institution></institution-wrap></funding-source><award-id>241995</award-id><principal-award-recipient><name><surname>Ropers</surname><given-names>Hans-Hilger</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>Reinhart Koselleck Grant</award-id><principal-award-recipient><name><surname>Langer</surname><given-names>Thomas</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>SFB665</award-id><principal-award-recipient><name><surname>Kaindl</surname><given-names>Angela M</given-names></name></principal-award-recipient></award-group><award-group id="par-10"><funding-source><institution-wrap><institution>Berlin Institute of Health</institution></institution-wrap></funding-source><award-id>BIH, CRG1</award-id><principal-award-recipient><name><surname>Kaindl</surname><given-names>Angela M</given-names></name></principal-award-recipient></award-group><award-group id="par-11"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001655</institution-id><institution>Deutscher Akademischer Austauschdienst</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Kaindl</surname><given-names>Angela M</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Mutations affecting a nuclear encoded metalloprotease cause of a new form of mitochondriopathy, highlighting the importance of this protease for mitochondrial function in humans.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mitochondriopathies often present as multisystemic diseases and can be caused by mutations in nuclear or mitochondrial DNA-encoded genes (<xref ref-type="bibr" rid="bib28">Nunnari, 2012</xref>). Here, we report a novel form of mitochondriopathy with infantile-onset developmental delay, muscle weakness, ataxia, and optic nerve atrophy caused by a homozygous mutation in the yeast mitochondrial escape 1-like 1 gene <italic>YME1L1</italic>.</p><p>YME1L1 was first identified in yeast, in a screen for gene products that elevate the rate of mitochondrial DNA migration to the nucleus (<xref ref-type="bibr" rid="bib5">Campbell et al., 1994</xref>; <xref ref-type="bibr" rid="bib40">Thorsness et al., 1993</xref>). The lack of yme1 impairs respiratory growth of yeast highlighting its important function in mitochondrial maintenance (<xref ref-type="bibr" rid="bib24">Nakai et al., 1995</xref>; <xref ref-type="bibr" rid="bib30">Pearce and Sherman, 1995</xref>). YME1L1, a member of the AAA family of ATPases (ATPases associated with a variety of cell activities), is a nuclear genome-encoded ATP-dependent metalloprotease embedded in the inner mitochondrial membrane (IM), with its protease domain facing the intermembrane space (IMS) (also termed <italic>i</italic>-AAA protease) (<xref ref-type="bibr" rid="bib21">Leonhard et al., 1996</xref>; <xref ref-type="bibr" rid="bib35">Shah et al., 2000</xref>; <xref ref-type="bibr" rid="bib47">Weber et al., 1996</xref>). Its import into mitochondria is accompanied by proteolytic processing via the mitochondrial processing peptidase (MPP), which cleaves off the mitochondrial targeting sequence (MTS) (<xref ref-type="bibr" rid="bib34">Rainey et al., 2006</xref>). The mature protein assembles into a homo-oligomeric complex within the IM (<xref ref-type="bibr" rid="bib21">Leonhard et al., 1996</xref>; <xref ref-type="bibr" rid="bib42">Van Dyck and Langer, 1999</xref>). YME1L1 degrades both IMS and IM proteins such as lipid transfer proteins (<xref ref-type="bibr" rid="bib31">Potting et al., 2013</xref>), components of protein translocases of the IM (<xref ref-type="bibr" rid="bib3">Baker et al., 2012</xref>; <xref ref-type="bibr" rid="bib33">Rainbolt et al., 2015</xref>), and the dynamin-like GTPase optic atrophy 1 (OPA1) (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib33">Rainbolt et al., 2015</xref>; <xref ref-type="bibr" rid="bib41">van der Bliek and Koehler, 2003</xref>).</p><p>The <italic>OPA1</italic> gene (MIM*605290), mutated in dominant optic atrophy (<xref ref-type="bibr" rid="bib11">Delettre et al., 2000</xref>), encodes a mediator of mitochondrial fusion that also orchestrates mitochondrial cristae morphogenesis (<xref ref-type="bibr" rid="bib6">Cipolat et al., 2004</xref>; <xref ref-type="bibr" rid="bib13">Frezza et al., 2006</xref>; <xref ref-type="bibr" rid="bib29">Olichon et al., 2003</xref>). OPA1 is processed by two peptidases in the IM, YME1L1 and OMA1 (overlapping with the m-AAA protease 1 homolog), which thereby balance fusion and fission of mitochondria (<xref ref-type="bibr" rid="bib22">MacVicar and Langer, 2016</xref>). Long OPA1 forms (L-OPA1) carry out mitochondrial fusion, while short forms (S-OPA1) are dispensable for fusion but contribute to mitochondrial fission when accumulated (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib12">Ehses et al., 2009</xref>; <xref ref-type="bibr" rid="bib15">Griparic et al., 2007</xref>; <xref ref-type="bibr" rid="bib17">Head et al., 2009</xref>; <xref ref-type="bibr" rid="bib37">Song et al., 2007</xref>). Loss of YME1L1 accelerates OMA1-dependent L-OPA1 cleavage, resulting in S-OPA1 accumulation, increased mitochondrial fission, and mitochondrial network fragmentation (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>). Despite previous attempts to link YME1L1 to human disease (<xref ref-type="bibr" rid="bib8">Coenen et al., 2005</xref>), its physiological role in humans remains to be elucidated.</p></sec><sec id="s2" sec-type="results|discussion"><title>Results and discussion</title><sec id="s2-1"><title>Homozygous <italic>YME1L1</italic> missense mutation causes mitochondriopathy</title><p>We report for the first time that patients with a homozygous mutation in the <italic>YME1L1</italic> gene develop an infantile-onset mitochondriopathy. Four affected children of healthy, consanguineous parents of Saudi Arabian descent were born at term without complications and with normal anthropometric data (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Medical history gave no indication for perinatal brain damage as a cause for the reported patient phenotypes. All four patients presented with intellectual disability, motor developmental delay, expressive speech delay, optic nerve atrophy associated with visual impairment, hearing impairment, but no facial dysmorphism (<xref ref-type="fig" rid="fig1">Figure 1B</xref>, <xref ref-type="table" rid="tbl1">Table 1</xref>). Inconsistent features were microcephaly (II.9, II.11) or macrocephaly (II.5), ataxia (II.5, II.8, II.9), hyperkinesia (II.9), and athetotic and stereotypic movements (II.11). Cranial MRI revealed leukoencephalopathy in all patients and signs of brain atrophy in patients II.9 and II.11 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Lactate levels and lactate/pyruvate ratios were elevated in blood and/or cerebrospinal fluid (CSF) of three patients as indicators of a mitochondriopathy, while alanine levels were normal in blood and cerebrospinal fluid samples. Analysis of a muscle biopsy specimen from patient II.5 revealed mitochondria with altered cristae morphology (so-called ‘parking lots’) and paracristalline inclusions as well as a neurogenic pattern with grouped fibers indicating denervation, but no conspicuous ragged red fibers in the Gomori trichrome staining (<xref ref-type="fig" rid="fig1">Figure 1D</xref>). Results of chromosome analysis, mitochondrial DNA sequencing and genetic testing for fragile X syndrome, Nijmegen breakage syndrome, and ataxia teleangiectasia were normal. Similarly, biochemical analyses gave no indication for adrenoleukodystrophy, GM1/GM2 gangliosidoses, Sandhoff disease, Tay-Sachs disease, Gaucher disease, Fabry disease, Krabbe disease, Mucopolysaccharidosis type IVB, neuronal ceroid-lipofuscinoses 1 and 2, and congenital disorder of glycosylation (CDG) syndrome (data not shown).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.002</object-id><label>Figure 1.</label><caption><title>Phenotype and genotype of patients with YME1L1 mitochondriopathy.</title><p>(<bold>A</bold>, <bold>B</bold>) The four affected patients are children of healthy, consanguineous parents of Saudi Arabian decent (□ male; ○ female; ◊ unknown gender; <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-inf1-v2"/>deceased; <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-inf2-v2"/>heterozygous, clinically not affected; ⚫/■ homozygous, affected; <inline-graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-inf3-v2"/>, consanguineous marriage). (<bold>C</bold>) Cranial MRIs reveal hyperintense changes (arrows) as a sign for leucencephalopathy, and cerebral atrophy (FLAIR, axial images). (<bold>D</bold>) Histological analysis of patient II.5 muscle biopsy specimen, from left to right: Gomori trichrome stain for muscle fibers revealed no conspicuous ragged red fibers indicative of a mitochondriopathy. Succinate dehydrogenase (SDH) and neuron specific enolase (NSE) staining revealed a neurogenic pattern with grouped fibers indicating denervation (magnification 200x). Electron microscopy (EM) revealed paracristalline inclusions (arrow) and altered cristae structure (“parking lots”, magnification 15,000x). (<bold>E</bold>) Whole exome sequencing discovered the homozygous mutation c.616C&gt;T in exon 5 of the <italic>YME1L1</italic> gene (NM_014263), localized at position 149 of the YME1L1 protein, and leading to an amino acid exchange of arginine to tryptophan in the mitochondrial targeting site (MTS; p.R149W, NP_055078). YME1L1 contains highly conserved domains: MTS, transmembrane domain (TM), ATPase domain (AAA+), motif of metalloprotease (Zinc) activity (HESGH). (<bold>F</bold>) Electropherogram depicting homozygous missense mutation in patient II.5, which is heterozygous in the father. (<bold>G</bold>) The mutation lies within a protein region, highly conserved throughout different species. (<bold>H</bold>) YME1L1 mRNA levels do not differ between patient and control primary human adult fibroblasts (Co, Control; II.5, patient II.5; ns, not significant; one-way ANOVA; p=0.2314; n=6 ) (<bold>I</bold>) Steady state levels of YME1L1 are below detection levels or profoundly reduced in cell lysates of patient II.5 YME1L1<sup>R149W</sup>; <italic>Yme1l1</italic> knockout mouse fibroblasts serve as negative controls. YME1L1 protein levels in mitchondrial compartment fractions can be found <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> (HAF, primary human adult fibroblasts; ACF, immortalized murine adult cardiac fibroblasts; MEF, immortalized murine embryonic fibroblast; Co, Control; II.5, patient II.5; WT, wild type; KO, <italic>Yme1l1</italic> knockout, n=5).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.002">http://dx.doi.org/10.7554/eLife.16078.002</ext-link></p><p><supplementary-material id="SD1-data"><object-id pub-id-type="doi">10.7554/eLife.16078.003</object-id><label>Figure 1—source data 1.</label><caption><title>Raw data Graph 1H.</title><p>Raw values of YME1L1 mRNA expression in human adult fibroblasts of controls and patient measured via TaqMan qPCR (n=6).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.003">http://dx.doi.org/10.7554/eLife.16078.003</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig1-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig1-v2"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.16078.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>(<bold>I</bold>) YME1L1<sup>R149W</sup> signal is barely detectable in total cell lysates (T), significantly reduced in the mitochondrial (M) but not present in the cytosolic (C) fraction of patient primary human adult fibroblasts (Co, Control; II.5, patient II.5; SDHA, succinate dehydrogenase; LDHA, lactate dehydrogenase; n=3).</title><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.004">http://dx.doi.org/10.7554/eLife.16078.004</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig1-figsupp1-v2"/></fig></fig-group><table-wrap id="tbl1" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.005</object-id><label>Table 1.</label><caption><p><italic>YME1L1</italic> mitochondriopathy phenotype.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.005">http://dx.doi.org/10.7554/eLife.16078.005</ext-link></p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" valign="top">Pedigree ID (gender)</th><th valign="top">II.5 (f)</th><th valign="top">II.8 (f)</th><th valign="top">II.9 (m)</th><th valign="top">II.11 (f)</th></tr></thead><tbody><tr><td colspan="3" valign="top">Age at last assessment (y)</td><td valign="top">15.8</td><td valign="top">12.3</td><td valign="top">10.3</td><td valign="top">5.2</td></tr><tr><td valign="top">Category</td><td valign="top">Feature</td><td valign="top">HPO</td><td align="left" valign="top"/><td colspan="2" valign="top"/><td valign="top"/></tr><tr><td colspan="7" valign="top"><italic>Inheritance</italic></td></tr><tr><td valign="top"/><td valign="top"/><td valign="top"/><td valign="top">AR</td><td valign="top">AR</td><td valign="top">AR</td><td valign="top">AR</td></tr><tr><td colspan="7" valign="top"><italic>Growth</italic></td></tr><tr><td valign="top">Height</td><td valign="top">Short stature <break/>SD;%</td><td valign="top">0004322</td><td valign="top">+ <break/>-2.19; 1</td><td valign="top">+ <break/>-2.09; 2</td><td valign="top">+ <break/>-1.89; 3</td><td valign="top">- <break/>0.38; 35</td></tr><tr><td valign="top">Weight</td><td valign="top">Low weight <break/>SD;%</td><td valign="top">0004325</td><td valign="top">+ <break/>-2.8; &lt;1</td><td valign="top">- <break/>-1.18; 12</td><td valign="top">- <break/>0.07; 53</td><td valign="top">- <break/>-1.35; 12</td></tr><tr><td colspan="7" valign="top"><italic>Neonatal period</italic></td></tr><tr><td valign="top"/><td valign="top">Neonatal asphyxia</td><td valign="top">0012768</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td colspan="7" valign="top"><italic>Head and Neck</italic></td></tr><tr><td valign="top">Head</td><td valign="top">Microcephaly</td><td valign="top">0000252</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Macrocephaly</td><td valign="top">0000256</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td></tr><tr><td valign="top">Face</td><td valign="top">Midface retrusion</td><td valign="top">0011800</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Congenital facial diplegia</td><td valign="top">0007188</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top">Ears</td><td valign="top">Hearing impairment</td><td valign="top">0000365</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Sensorineural hearing impairment</td><td valign="top">0000407</td><td valign="top">n.a.</td><td valign="top">n.a.</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Macrotia</td><td valign="top">0000400</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top">Eyes</td><td valign="top">Pigmentary retinopathy</td><td valign="top">0000580</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Optic nerve hypoplasia</td><td valign="top">0000609</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Cherry red spot of the macula</td><td valign="top">0010729</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Strabismus</td><td valign="top">0000486</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Hypermetropia</td><td valign="top">0000540</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Myopia</td><td valign="top">0000545</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Amblyopia</td><td valign="top">0000646</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Abnormality of visual evoked potentials</td><td valign="top">0000649</td><td valign="top">n.a.</td><td valign="top">-</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td colspan="7" valign="top"><italic>Abdomen</italic></td></tr><tr><td valign="top">Gastro-intestinal</td><td valign="top">Constipation (in infancy)</td><td valign="top">0002019</td><td valign="top">+</td><td valign="top">n.a.</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top">Spleen</td><td valign="top">Splenomegaly</td><td valign="top">0001744</td><td valign="top">+</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td colspan="7" valign="top">Skeletal</td></tr><tr><td valign="top">Feet</td><td valign="top">Bilateral talipes equinovarus</td><td valign="top">0001776</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td colspan="7" valign="top"><italic>Muscle, soft tissue</italic></td></tr><tr><td valign="top"/><td valign="top">Increased variability in muscle fiber diameter</td><td valign="top">0003557</td><td valign="top">+</td><td valign="top">n.a.</td><td valign="top">n.a.</td><td valign="top">n.a.</td></tr><tr><td colspan="7" valign="top"><italic>Neurologic</italic></td></tr><tr><td valign="top">CNS</td><td valign="top">Hypotonia, neonatal, generalized</td><td valign="top">0008935</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Infantile muscular hypotonia</td><td valign="top">0008947</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Global developmental delay (onset, months)</td><td valign="top">0001263</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+ (6)</td></tr><tr><td valign="top"/><td valign="top">Motor delay</td><td valign="top">0001270</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Gait apraxia</td><td valign="top">0010521</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Athetosis</td><td valign="top">0002305</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Intellectual disability, moderate; (IQ)</td><td valign="top">0002342</td><td valign="top">+ (48)</td><td valign="top">n.a.</td><td valign="top">n.a.</td><td valign="top">+ (39)</td></tr><tr><td valign="top"/><td valign="top">Incomprehensible speech</td><td valign="top">0002546</td><td valign="top">n.a.</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Poor speech</td><td valign="top">0002465</td><td valign="top">n.a.</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Absent speech</td><td valign="top">0001344</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Seizures (onset, months)</td><td valign="top">0001250</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+ (6)</td></tr><tr><td valign="top"/><td valign="top">Dysmetria</td><td valign="top">0001310</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Ataxia</td><td valign="top">0001251</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Brain atrophy</td><td valign="top">0012444</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Ventriculomegaly</td><td valign="top">0002119</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Delayed CNS myelination</td><td valign="top">0002188</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Abnormality of the cerebral white matter</td><td valign="top">0002500</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Abnormality of the basal ganglia</td><td valign="top">0002134</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Cerebellar hypoplasia (progressive)</td><td valign="top">0001321</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">EEG with focal sharp waves</td><td valign="top">0011196</td><td valign="top">n.a.</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Abnormal auditory evoked potentials</td><td valign="top">0006958</td><td valign="top">n.a.</td><td valign="top">n.a.</td><td valign="top">+</td><td valign="top">+</td></tr><tr><td valign="top">PNS</td><td valign="top">Decreased sensory nerve conduction velocity</td><td valign="top">0003448</td><td valign="top">-</td><td valign="top">+</td><td valign="top">n.a.</td><td valign="top">-</td></tr><tr><td valign="top">Behavioural Psychiatric</td><td valign="top">Hyperactivity</td><td valign="top">0000752</td><td valign="top">-</td><td valign="top">+</td><td valign="top">-</td><td valign="top">-</td></tr><tr><td valign="top"/><td valign="top">Attention deficit hyperactivity disorder</td><td valign="top">0007018</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td valign="top"/><td valign="top">Stereotypical body rocking</td><td valign="top">0012172</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr><tr><td colspan="7" valign="top"><italic>Laboratory anomalies</italic></td></tr><tr><td valign="top"/><td valign="top">Mildly elevated creatine phosphokinase</td><td valign="top">0008180</td><td valign="top">-</td><td valign="top">-</td><td valign="top">-</td><td valign="top">+</td></tr></tbody></table></table-wrap></p><p>To identify the genetic basis of the disease, we performed whole-exome sequencing (WES) followed by Sanger sequencing and bioinformatic analysis. We thereby identified a homozygous missense mutation in a highly conserved region of the <italic>YME1L1</italic> gene in the affected children (c.616C&gt;T, NM_014263; chr10:27425300; GRCh 38.5, raw data available: sequence reads archive (SDA) accession no. SRP073309) that segregates with the phenotype in the index family. We did not detect mutations in other genes linked previously to neurologic diseases. (<xref ref-type="bibr" rid="bib10">De Michele et al., 1998</xref>; <xref ref-type="bibr" rid="bib16">Hazan et al., 1994</xref>; <xref ref-type="bibr" rid="bib46">Warnecke et al., 2007</xref>). The <italic>YME1L1</italic> gene mutation c.616C&gt;T causes the exchange of highly conserved hydrophilic arginine to hydrophobic tryptophan (p.R149W, NP_055078) within the N-terminal MTS (<xref ref-type="fig" rid="fig1">Figure 1E–G</xref>). YME1L1<sup>R149W</sup> was below detection levels or profoundly reduced in patient whole cell lysates and in mitochondrial enriched fractions of patient fibroblasts, while mRNA levels remain unaltered (<xref ref-type="fig" rid="fig1">Figure 1H,I</xref>, <xref ref-type="supplementary-material" rid="SD1-data">Figure 1–source data 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1–figure supplement 1</xref>). These results identify a disease-causing mutation in arginine 149 of YME1L1, which impairs protein accumulation.</p></sec><sec id="s2-2"><title>YME1L1<sup>R149W</sup> abrogates maturation of YME1L1 upon import into mitochondria</title><p>The affected amino acid residue arginine 149 is present within a predicted mitochondrial targeting sequence of YME1L1 and may affect targeting of the mutant protein to mitochondria. We therefore transiently expressed YME1L1 and YME1L1<sup>R149W</sup> in <italic>YME1L1</italic><sup>-/-</sup> HeLa cells generated by CRISPR/Cas9-mediated genome editing (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Both YME1L1 and YME1L1<sup>R149W</sup> co-localized with the mitochondrial marker protein ATPase subunit ß, demonstrating mitochondrial targeting of the mutant protein. Consistently, inhibition of the proteasome did not stabilize mutant YME1L1 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), suggesting that reduced levels of YME1L1<sup>R149W</sup> are not caused by proteasomal degradation of non-imported YME1L1 precursor proteins. We therefore excluded a degradation of mutant YME1L1<sup>R149W</sup> via the proteasome.<fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.006</object-id><label>Figure 2.</label><caption><title>Mutation of arginine 149 impairs maturation of YME1L1 by MPP upon import into mitochondria.</title><p>(<bold>A</bold>) YME1L1<sup>R149W</sup> is targeted to mitochondria. HeLa cells were transiently transfected with wild-type YME1L1, YME1L1<sup>R149W</sup> or the empty vector (EV) as control. Cells were analyzed by indirect immunofluorescence and co-localization of the immunofluorescent signals of antibodies against YME1L1 and ATP Synthase subunit beta (ATPase-ß) (WT, Wildtype; YME1L1<sup>-/-</sup>, Knockout; EV, empty vector; YME1L1<sup>R149W</sup>, patient mutation; Scale bar 10 µM). (<bold>B</bold>) Inhibition of the proteasome with MG132 (20 mM, 18 h) does not stabilize precursor or mature YME1L1 in Flp-In T-Rex HEK293T cells expressing YME1L1 or YME1L1 mutant variants: R149W, E381Q or R149W/E381Q. P4D1 antibodies were used as a control for ubiquitin accumulation and proteasome inhibition. (R149W, patient mutation; E381Q, dominant negative mutation of ATPase domain; R149W/E381Q, double mutant; *, unspecific signal; p, premature; m, mature; PoS, Ponceau staining; n=2). (<bold>C</bold>) Maturation of YME1L1 is mediated by mitochondrial processing peptidase (MPP) and impaired upon mutation of arginine 149. After site-directed mutagenesis of N-terminal arginine residues in YME1L1, the mutant proteins were expressed in a cell-free system and processing by recombinant MPP was examined (WT, wild type YME1L1; p, premature m, mature, n=2–3). (<bold>D</bold>) Cell-free MPP cleavage-assay: MPP can cleave YME1L1 but not YME1L1<sup>R149W</sup> from the premature to its mature form (min, minutes; p, premature; m, mature; YME1L1<sup>R149W</sup>, patient mutation; n=3).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.006">http://dx.doi.org/10.7554/eLife.16078.006</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig2-v2"/></fig></p><p>Nuclear-encoded YME1L1 requires cleavage of the MTS from premature YME1L1 (~80 kDa) upon import into mitochondria to give rise to the mature protein (~63 kDa), which is able to assemble into a homooligomeric proteolytic complex in the IM (<xref ref-type="bibr" rid="bib14">Graef et al., 2007</xref>; <xref ref-type="bibr" rid="bib39">Stiburek et al., 2012</xref>; <xref ref-type="bibr" rid="bib42">Van Dyck and Langer, 1999</xref>). MTS cleavage of YME1L1 precursor is bioinformatically predicted to be mediated by MPP (NM_014263; Mitoprot) (<xref ref-type="bibr" rid="bib7">Claros and Vincens, 1996</xref>). Since the identified human mutation affects an arginine and such residues are known to function as MPP recognition and cleavage sites (<xref ref-type="bibr" rid="bib26">Niidome et al., 1994</xref>), we asked whether arginine 149 is part of the MPP cleavage site in YME1L1. We mutated various arginine residues in the N-terminal region of YME1L1 and analyzed maturation of corresponding YME1L1 variants synthesized in a cell-free expression system using recombinant MPP (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). YME1L1 was converted by MPP in its mature form (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Mutation of arginine at position 149 abrogated MPP-mediated processing of YME1L1, suggesting that amino acid 151 forms the N-terminal amino acid of mature YME1L1. Replacement of arginine 149 by tryptophan similarly abolished maturation of YME1L1 by MPP in vitro (<xref ref-type="fig" rid="fig2">Figure 2D</xref>).</p></sec><sec id="s2-3"><title>YME1L1<sup>R149W</sup> undergoes rapid proteolysis</title><p>Grossly reduced YME1L1 protein levels coinciding with unaltered mRNA levels indicate a post-transcriptional mechanism responsible for the reduction of YME1L1<sup>R149W</sup>. Stabilization of the precursor form of YME1L1 by abolishing the MPP recognition site may allow another peptidase to cleave YME1L1. To identify the latter mechanism, we screened candidate mitochondrial proteases for their effect on YME1L1 and YME1L1<sup>R149W</sup> stably expressed in HEK293T cells, but could not detect a difference in YME1L1/YME1L1<sup>R149W</sup> level upon depletion of individual proteases (data not shown). However, by preventing the proteolytic activity of YME1L1 upon ectopic expression of the dominant-negative YME1L1<sup>E381Q</sup>, harboring a point mutation in the ATPase domain, we were able to stabilize not only the known YME1L1 substrate PRELID1 (<xref ref-type="bibr" rid="bib31">Potting et al., 2013</xref>) but also observed accumulation of both the precursor and mature forms of YME1L1 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The mature form of YME1L1 remained stable in cells harboring YME1L1<sup>E381Q</sup> upon further incubation in the presence of cycloheximide, while ectopic expression of the wild type variant resulted in significantly lower levels of YME1L1 and reduced stability (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). These observations point to an auto-catalytic degradation of YME1L1<sup>R149W</sup>. We therefore combined the dominant negative mutation E381Q with the pathogenic mutation R149W in YME1L1 in cis and examined the stability of this variant (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). We observed an accumulation of mature YME1L1<sup>R149W/E381Q</sup> upon ectopic expression in HEK293T cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Both mature YME1L1<sup>R149W/E381Q</sup> and larger forms with a similar size to the precursor form of YME1L1 accumulated in these cells. Stabilization of the precursor form of YME1L1 in these cells may allow another peptidase to cleave YME1L1 resulting in the accumulation of slightly smaller forms of YME1L1. These results suggest that YME1L1 mediates degradation of mutant YME1L1<sup>R149W</sup>, which accumulates in the precursor form due to the mutation of the MPP cleavage site and thus is likely recognized as a misfolded protein in the IM. As the mutant YME1L1 variants were expressed in wild type HEK293T cells, we cannot distinguish whether degradation of YME1L1<sup>R149W</sup> occurs intramolecularly and/or by endogenous YME1L1 under these experimental conditions. However, the lack of wild-type YME1L1 in patient cells with homozygous <italic>YME1L1</italic> mutations together with our ectopic expression studies argue for auto-catalytic degradation of YME1L1<sup>R149W</sup>.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.007</object-id><label>Figure 3.</label><caption><title>Mutation of arginine 149 destabilizes YME1L1 but retains residual YME1L activity.</title><p>(<bold>A</bold>) Stability of YME1L1 or YME1L1 mutant variants (R149W, E381Q and R149W/E381Q) expressed in Flp-In T-Rex HEK293T cells. The dominant negative E381Q mutation in the ATPase domain of YME1L1 prevents degradation of YME1L1<sup>R149W</sup> (E381Q, dominant negative mutation of ATPase domain; R149W, patient mutation; R149W/E381Q, double mutant; CHX, cycloheximide; h, hours; p, premature; m, mature; SDHA, succinate dehydrogenase; n=2). (<bold>B</bold>) Homozygous mutation in <italic>YME1L1</italic> results in an accumulation of PRELID1 in the human patient. <italic>Yme1l1</italic> knockout mouse fibroblasts serve as positive controls to demonstrate impaired proteolysis of PRELID1 (HAF, human adult primary fibroblasts; ACF, immortalized murine adult cardiac fibroblasts; MEF, immortalized murine embryonic fibroblast; Co, Control; II.5, patient; WT, wild type; KO, knockout; n=5). (<bold>C</bold>) Mutation of arginine 149 of YME1L1 impairs processing of OPA1 with a decrease of short OPA1 form d levels. The formation of OPA1 form d indicates residual YME1L1 activity in human patient fibroblasts (immort. HAF, immortalized human adult fibroblasts; ACF, immortalized murine adult cardiac fibroblasts; MEF, immortalized murine embryonic fibroblast; Co, Control; II.5, patient; WT, wild type; KO, knockout; n=6). The schematic diagram illustrates the proteolytic processing of OPA1 by YME1L1 on processing site 2 (S2) and OMA1 on processing site 1 (S1). The presence of long OPA1 forms (L-OPA1) is required for the maintenance of mitochondrial inner membrane fusion, whereas accumulation of short OPA1 forms (S-OPA1) is associated with accelerated fission. (<bold>D</bold>) Mitochondria-enriched membrane fractions from Flp-In T-Rex HEK293T cells expressing YME1L1 or YME1L1 mutant variants (R149W, E381Q and R149W/E381Q) were solubilized in digitonin and analyzed by sucrose gradient centrifugation. Fractions were collected and separated on SDS-PAGE for immunoblotting to detect high MW complexes of YME1L1. HSP60 complexes were used as a control (M, mitochondrial input, P, S, pellet and supernatant fraction after solubilization; HSP60, heat shock protein 60; E381Q, dominant negative mutation of ATPase domain; R149W, patient mutation; R149W/E381Q, double mutant). (<bold>E</bold>) Premature YME1L1/ YME1L1<sup>R149W</sup> is imported into the mitochondrial matrix via translocons of the outer mitochondrial membrane (TOMM) and inner mitochondrial membrane (TIMM). Here, MPP binds and cleaves the N-terminal mitochondrial targeting site (MTS) from premature YME1L1 but not YME1L1<sup>R149W</sup>, which then allows the mature and premature YME1L1<sup>R149W</sup> protein to assemble as proteolytic complex.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.007">http://dx.doi.org/10.7554/eLife.16078.007</ext-link></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig3-v2"/></fig></p></sec><sec id="s2-4"><title>Impaired proteolysis by YME1L1<sup>R149W</sup></title><p>To confirm a functional impairment of YME1L1<sup>R149W</sup>, we analyzed the effect of YME1L1<sup>R149W</sup> on two substrate proteins, the protein of relevant evolutionary and lymphoid interest (PRELID1) and OPA1, in patient-derived skin fibroblasts. PRELID1, a lipid transfer protein for phosphatidic acid in the IMS, is constitutively degraded by YME1L1 (<xref ref-type="bibr" rid="bib31">Potting et al., 2013</xref>). PRELID1 accumulated in primary human fibroblasts (HAF) of patient II.5 when compared to controls (<xref ref-type="fig" rid="fig3">Figure 3B</xref>), consistent with the low levels of YME1L1<sup>R149W</sup> present in mitochondria (<xref ref-type="fig" rid="fig1">Figure 1I</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1–figure supplement 1</xref>). Deletion of murine <italic>Yme1l1</italic> leads to accelerated processing of L-OPA1 by OMA1 (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Rainbolt et al., 2016</xref>) and drives mitochondrial fragmentation in vitro (<xref ref-type="bibr" rid="bib2">Baker et al., 2014</xref>) and in vivo (<xref ref-type="bibr" rid="bib20">Korwitz et al., 2016</xref>; <xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>). We similarly identified an altered cleavage pattern of OPA1 in patient cells, albeit more modestly than in knockout mouse cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>).</p><p>This suggests that YME1L1<sup>R149W</sup> retains proteolytic activity. As proteolysis by YME1L1 depends on its oligomerization, we examined in further experiments the assembly of YME1L1<sup>R149W</sup> expressed in HEK293 cells by sucrose gradient centrifugation (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). To allow detection of YME1L1<sup>R149W</sup> precursor forms and impair its degradation, we also examined the assembly of YME1L1<sup>R149W/E381Q</sup> expressed in HEK293 cells. Similar to YME1L1, the mutant variants of YME1L1 were recovered in protein complexes of ~2 MDa (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). Notably, we also observed assembly of the precursor form of YME1L1<sup>R149W/E381Q</sup>, demonstrating that the disease-causing mutation R149W does not impair the formation of the <italic>i</italic>-AAA protease complex. Thus, assembled YME1L1<sup>R149W</sup> precursor forms may explain the residual activity of YME1L1 in patient fibroblasts (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Alternatively, and not mutually exclusive, low levels of mature YME1L1<sup>R149W</sup> may maintain residual proteolytic activity in the patient system.</p><p>Together, we conclude that YME1L1<sup>R149W</sup> is a hypomorphic allele that retains partial YME1L1 activity, which reconciles the embryonic lethality (<xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>) of <italic>Yme1l1</italic> knockout mice with the milder phenotype in our patients with a homozygous <italic>YME1L1</italic> missense mutation.</p></sec><sec id="s2-5"><title>YME1L1<sup>R149W</sup> causes mitochondrial fragmentation</title><p>Given the role of unbalanced mitochondrial dynamics in neurodegenerative diseases (<xref ref-type="bibr" rid="bib4">Burté et al., 2015</xref>) and the observed, impaired OPA1 processing, we focused our attention on mitochondrial morphology in patient fibroblasts. We detected an increase in shortened and fragmented mitochondrial networks in HAF of patient II.5 relative to a control (<xref ref-type="fig" rid="fig4">Figure 4A,B</xref>, <xref ref-type="other" rid="media1">Videos 1</xref>–<xref ref-type="other" rid="media4">4</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 4–source data 1</xref>), consistent with the more severe fragmentation phenotype in <italic>Yme1l1</italic> KO mouse fibroblasts (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>). We therefore transiently expressed human YME1L1<sup>R149W</sup> and YME1L1 in murine adult cardiac <italic>Yme1l1<sup>-/-</sup></italic>fibroblasts (<xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>) and observed that human YME1L1 but not YME1L1<sup>R149W</sup> was able to complement mitochondrial fragmentation. Of note, the human mutant variant was still able to partially tubulate mitochondria (<xref ref-type="fig" rid="fig4">Figure 4C,D</xref>, <xref ref-type="supplementary-material" rid="SD2-data">Figure 4–source data 1</xref>), consistent with the notion that YME1L1<sup>R149W</sup> retains residual function.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.008</object-id><label>Figure 4.</label><caption><title>YME1L1<sup>R149W</sup> causes mitochondrial fragmentation.</title><p>(<bold>A</bold>, <bold>B</bold>) YME1L1<sup>R149W</sup> causes fragmentation (fragmentation or short tubules) of mitochondrial networks in patient fibroblasts (Co, Control, II.5, patient II.5; one-way ANOVA; n=150–200 cells; 4 replicates; scale bar 10 µm). (<bold>C</bold>) Co-transfection of mitochondrial GFP and human YME1L1/ YME1L1<sup>R149W</sup> protein in WT and <italic>Yme1l1</italic><sup>-/-</sup> MEFs revealed that YME1L1 but not YME1L1<sup>R149W</sup>can rescue mitochondrial fragmentation in <italic>Yme1l1</italic><sup>-/-</sup> MEFs and (<bold>D</bold>) increases the number of cells with tubular networks. Expression of YME1L1<sup>R149W</sup> partially rescues the fragmentation phenotype. In WT MEFs, YME1L1<sup>R149W</sup> expression results in only a mild, but not significant decline of cells with a tubular mitochondrial network (WT, wildtype; Yme1l1<sup>-/-</sup>, Yme1l1 Knockout; two-way ANOVA; n=3; scale bar 10 µm; **p&lt;0.01; ***p&lt;0.001; ****p&lt;0.0001).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.008">http://dx.doi.org/10.7554/eLife.16078.008</ext-link></p><p><supplementary-material id="SD2-data"><object-id pub-id-type="doi">10.7554/eLife.16078.009</object-id><label>Figure 4—source data 1.</label><caption><title>Raw data Graph 4B.</title><p>Relative mitochondrial morphology quantification after immunocytochemistry with TOMM20 antibody and DAPI in human adult fibroblasts of control and patient (n=150–200 cells, 4 replicates).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.009">http://dx.doi.org/10.7554/eLife.16078.009</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig4-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD3-data"><object-id pub-id-type="doi">10.7554/eLife.16078.010</object-id><label>Figure 4—source data 2.</label><caption><title>Raw data Graph 4D.</title><p>Relative mitochondrial morphology quantification after immunocytochemistry with TOMM20 antibody and DAPI in WT and <italic>Yme1l1<sup>-/-</sup></italic> adult cardiac murine fibroblasts overexpressing YME1L1 or YME1L1<sup>R149W</sup> (n=3).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.010">http://dx.doi.org/10.7554/eLife.16078.010</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig4-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig4-v2"/></fig><media content-type="glencoe play-in-place height-250 width-310" id="media1" mime-subtype="mp4" mimetype="video" xlink:href="elife-16078-media1.mp4"><object-id pub-id-type="doi">10.7554/eLife.16078.011</object-id><label>Video 1.</label><caption><title>Three dimensional rendering of mitochondrial structure of a control fibroblast.</title><p>MitoTracker Deep Red- mitochondria; DAPI-nucleus.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.011">http://dx.doi.org/10.7554/eLife.16078.011</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media2" mime-subtype="mp4" mimetype="video" xlink:href="elife-16078-media2.mp4"><object-id pub-id-type="doi">10.7554/eLife.16078.012</object-id><label>Video 2.</label><caption><title>Three dimensional rendering of mitochondrial structure of a patient II.5 fibroblast.</title><p>MitoTracker Deep Red- mitochondria; DAPI-nucleus.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.012">http://dx.doi.org/10.7554/eLife.16078.012</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media3" mime-subtype="mp4" mimetype="video" xlink:href="elife-16078-media3.mp4"><object-id pub-id-type="doi">10.7554/eLife.16078.013</object-id><label>Video 3.</label><caption><title>Mitochondrial dynamics in a control fibroblast.</title><p>MitoTracker Green-mitochondria, live cell imaging.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.013">http://dx.doi.org/10.7554/eLife.16078.013</ext-link></p></caption></media><media content-type="glencoe play-in-place height-250 width-310" id="media4" mime-subtype="mp4" mimetype="video" xlink:href="elife-16078-media4.mp4"><object-id pub-id-type="doi">10.7554/eLife.16078.014</object-id><label>Video 4.</label><caption><title>Mitochondrial dynamics in a patient II.5 fibroblast.</title><p>MitoTracker Green-mitochondria, live cell imaging.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.014">http://dx.doi.org/10.7554/eLife.16078.014</ext-link></p></caption></media></p></sec><sec id="s2-6"><title>YME1L1<sup>R149W</sup> impairs cell proliferation</title><p>To further address the pathophysiological mechanism underlying the neurological phenotype in humans, we analyzed proliferation and apoptosis of HAF. Proliferation of patient II.5 fibroblasts was significantly reduced compared to those of healthy controls, while the level of induced apoptotic cell death remained unaffected (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5–source data 1</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5–source data 1</xref>, <xref ref-type="supplementary-material" rid="SD4-data">Figure 5–source data 1</xref>). Analysis of the respiratory chain in patient fibroblasts revealed the specific enzymatic activities to be within the normal physiological range and subunit levels to be unaltered (<xref ref-type="fig" rid="fig5">Figure 5D,E</xref>), consistent with the observation in Yme1l1–depleted hearts (<xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>). However, the reduced steady state levels of various mitochondrial compartment markers in patient cells indicate a general reduction of mitochondrial mass in YME1L1<sup>R149W</sup> cells (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, <xref ref-type="fig" rid="fig5">Figure 5F</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.16078.015</object-id><label>Figure 5.</label><caption><title>YME1L1 mutation impairs fibroblast cell growth and proliferation.</title><p>(<bold>A</bold>) Significant reduction of cell culture growth (y-axis scale *10<sup>4</sup>) and (<bold>B</bold>) proliferation of patient primary human adult fibroblasts after 120h under culture conditions (Co, Control; II.5, patient II.5; one-way ANOVA; ***p&lt;0.001; ****p&lt;0.0001; n=5 ). (<bold>C</bold>) No increase in apoptosis-sensitivity upon 2 µM staurosporine (STS) treatment in patient HAF after 6h (SDS-PAGE for cleaved PARP level (cPARP) (Co, Control; II.5, patient II.5; one-way ANOVA; p6h = 0.4283; n=3; ). (<bold>D</bold>) Normal respiratory chain subunit activity in patient HAF (U, units; mU, milli U; CS, Citrate synthase). (<bold>E</bold>) Cytochrome c oxidase subunit 4 (COX4) and NADH ubiquinone oxidoreductase 1 beta subcomplex 6 (NDUFB6) protein levels were not elevated in patient fibroblasts (Co, Control; II.5, patient II.5; n=3). (<bold>F</bold>) Decreased levels of mitochondrial compartment markers TOMM20 (translocon of outer mitochondrial membrane 20) for the outer membrane (OM), Cytochrome c for the intermembrane space (IMS), SDHA (succinate dehydrogenase) for the inner membrane (IM), and Cyclophilin D for the matrix in whole cell lysates of patient II.5 (Co, Control; II.5, patient II.5; n=3).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.015">http://dx.doi.org/10.7554/eLife.16078.015</ext-link></p><p><supplementary-material id="SD4-data"><object-id pub-id-type="doi">10.7554/eLife.16078.016</object-id><label>Figure 5—source data 1.</label><caption><title>Raw data Graph 5A.</title><p>Raw values of fluorometric measurement with Cell-titer Blue Cell Viability Assay application in human adult fibroblasts of controls and patient (n=5).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.016">http://dx.doi.org/10.7554/eLife.16078.016</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig5-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD5-data"><object-id pub-id-type="doi">10.7554/eLife.16078.017</object-id><label>Figure 5—source data 2.</label><caption><title>Raw data Graph 5B.</title><p>Raw values of colorimetric measurement with BrdU Cell Proliferation ELISA Assay application in human adult fibroblasts of controls and patient (n=5).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.017">http://dx.doi.org/10.7554/eLife.16078.017</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig5-data2-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="SD6-data"><object-id pub-id-type="doi">10.7554/eLife.16078.018</object-id><label>Figure 5—source data 3.</label><caption><title>Raw data Graph 5C.</title><p>Raw values of cleaved-PARP antibody signal intensity after staurosporine treatment in human adult fibroblasts of controls and patient and SDS-Page (n=3).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.018">http://dx.doi.org/10.7554/eLife.16078.018</ext-link></p></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-16078-fig5-data3-v2.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="x-tiff" mimetype="image" xlink:href="elife-16078-fig5-v2"/></fig></p><p>Here we report a new form of infantile-onset mitochondriopathy caused by a homozygous mutation in the <italic>YME1L1</italic> gene. Patients suffer from severe intellectual disability, muscular impairments, and optic nerve atrophy. In contrast to complete gene deletion in the mouse (<xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>), the homozygous c.616C&lt;T missense mutation is compatible with life, likely owing to the residual function of YME1L1<sup>R149W</sup>. We demonstrate that the missense mutation affects the MPP processing site and impairs YME1L1 maturation, leading to its rapid degradation. We further show that the YME1L1<sup>R149W</sup> leads to a proliferation defect, abnormal OPA1 processing and mitochondrial fragmentation. Since fusion and fission of mitochondria are essential to preserve cellular functions, it is conceivable that defects in these processes, contribute to the patient phenotype in a cell-type specific manner. With our findings, we reveal an important role of YME1L1 for the maintenance of mitochondrial morphology in humans and link a loss of YME1L1 function to disease. YME1L1 thereby joins other members of the AAA family of ATPases that have already been linked to neurologic disease, such as spastin (<italic>SPG4</italic>, MIM*6042779 and paraplegin (<italic>SPG7</italic>, MIM*602783) gene, and in the gene encoding the YME1L1 substrate optic atrophy 1 (<italic>OPA1</italic>, MIM*605290) (<xref ref-type="bibr" rid="bib10">De Michele et al., 1998</xref>; <xref ref-type="bibr" rid="bib16">Hazan et al., 1994</xref>; <xref ref-type="bibr" rid="bib25">Nielsen et al., 1997</xref>; <xref ref-type="bibr" rid="bib46">Warnecke et al., 2007</xref>). Future studies on further patients are required to determine the full phenotype spectrum associated with <italic>YME1L1</italic> gene mutations.</p></sec></sec><sec id="s3" sec-type="materials|methods"><title>Material and methods</title><sec id="s3-1"><title>Subjects</title><p>Informed consent was obtained from the parents of the patients for the molecular genetic analysis, the publication of clinical data, photos, magnetic resonance images (MRI), and studies on fibroblasts. The human study was approved by the local ethics committee of the Charité (approval no. EA1/212/08).</p></sec><sec id="s3-2"><title>Genetic analyses</title><p>Homozygosity linkage intervals (chr10:24,333,063–49,978,774, LOD=2.533) with LOD&gt;2 and length &gt;1 Mb were identified using the Affymetrix SNP array 6.0. For whole exome sequencing, 1 µg genomic DNA extracted from peripheral blood was enriched by Agilent SureSelect Human All Exon enrichment kit version 3 and deep-sequenced by Illumina Hiseq2000 sequencer in a 101 bp single-end mode. The output sequences amounted to 12 Gb and &gt;94% of the exon-coding regions were covered by at least 20 folds. The data analysis pipeline considered linkage interval, pathogenicity of variants, allele frequency in polymorphism databases (1000Genome, ESP, and an in-house database including 868 individual exomes of Middle East origin), functional involvement of specific genes, thus resulting in the identification of a homozygous <italic>YME1L1</italic> gene mutation (chr10p12.1) (<xref ref-type="bibr" rid="bib23">Najmabadi et al., 2011</xref>). We confirmed the absence of homozygous deleterious variants (missense, nonsense, frameshift, splice site change) in <italic>YME1L1</italic> in the NHLBI Exome Sequencing Project (ESP, <ext-link ext-link-type="uri" xlink:href="http://evs.gs.washington.edu/EVS/">http://evs.gs.washington.edu/EVS/</ext-link>; ExAC 0.3 <ext-link ext-link-type="uri" xlink:href="http://exac.broadinstitute.org/">http://exac.broadinstitute.org/</ext-link>), the 1000 Genome database (<ext-link ext-link-type="uri" xlink:href="http://www.1000genomes.org/">http://www.1000genomes.org/</ext-link>), the dbSNP138 (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/SNP/">http://www.ncbi.nlm.nih.gov/SNP/</ext-link>), and our in-house 898 Middle East origin exome database. The raw data is available under the sequence reads archive (SDA) accession no. SRP073309.</p><p>Sanger sequencing of the <italic>YME1L1</italic> gene (NM_014263, GRCh 38.5) confirmed the mutation in the patients and established the genotype in the other family members and in additional families.</p></sec><sec id="s3-3"><title>Mouse and human fibroblasts</title><p>HAF were established from skin biopsies derived from patient II.5 and unrelated controls (Co1-3). MEF and adult cardiac fibroblasts (ACF) were derived from <italic>Yme1l1</italic> mutant mice (<italic>Yme1l1</italic><sup>loxP/loxP</sup>) as described previously (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Wai et al., 2015</xref>; <xref ref-type="bibr" rid="bib48">Yao and Shoubridge, 1999</xref>). HAF, MEF, and ACF were cultured in high glucose Dulbecco’s modified Eagle’s medium (Gibco, Darmstadt, Germany) supplemented with 15%, 10%, and 10% fetal bovine serum (FBS, Biochrome, Berlin, Germany; Life Technologies; Carlsbad, California), respectively, and 1% penicillin-streptomycin (Sigma Aldrich; St. Louis, Missouri). Fibroblasts were immortalized by stable expression of hTERT and E7 (<xref ref-type="bibr" rid="bib49">Zhu et al., 1998</xref>).</p></sec><sec id="s3-4"><title>Generation of <italic>YME1L1</italic><sup>-/-</sup> HeLa cells</title><p><italic>YME1L1</italic> KO cells were generated using the CRISPR/Cas9 system. Guide RNA (gRNA) and Cas9 were expressed using the px330 expression vector (<xref ref-type="bibr" rid="bib9">Cong et al., 2013</xref>). The following gRNA target sequence was used: 5’-GGAACCGACCATATTACAACAGG-3´ (recommended by the lab of Alexander van der Bliek). Single clones were obtained by serial dilution after transfection and screened by SDS-PAGE and immunoblotting.</p></sec><sec id="s3-5"><title>qPCR</title><p>DNA extraction and cDNA synthesis were performed with established methods reported previously (<xref ref-type="bibr" rid="bib18">Issa et al., 2013</xref>). To specifically amplify and detect murine <italic>Yme1l1</italic>, human <italic>YME1L1, Hprt</italic> (Hypoxanthine-guanine phosphoribosyl-transferase, reference gene), and <italic>RPII</italic> (RNA polymerase II, reference gene) cDNA, we designed sets of primers and TaqMan probes specified in <xref ref-type="supplementary-material" rid="SD7-data">Supplementary file 1A</xref> using the GenScript real-time PCR (TaqMan) Primer Design online software (www.genscript.com). qPCR and quantification was performed as described previously (<xref ref-type="bibr" rid="bib18">Issa et al., 2013</xref>), and further statistics were performed using the GraphPad Prism 5 Software (GraphPad Software Inc., La Jolla, California).</p></sec><sec id="s3-6"><title>Western blot</title><p>Protein whole lysate extraction, fractionated mitochondrial and cytosolic protein extraction, and Western blots were performed with established methods reported previously (<xref ref-type="bibr" rid="bib18">Issa et al., 2013</xref>; <xref ref-type="bibr" rid="bib31">Potting et al., 2013</xref>). Antibodies are listed in <xref ref-type="supplementary-material" rid="SD7-data">Supplementary file 1B</xref>.</p></sec><sec id="s3-7"><title>Isolation of a crude mitochondrial fraction</title><p>The protocol was adapted from (<xref ref-type="bibr" rid="bib43">Vogel et al., 2005</xref>). Cells were harvested using trypsin and washed three times in PBS to remove the trypsin. Subsequently, the cells were resuspended in 3 ml isotonic Buffer (0,25 M Sucrose, 5 mM Tris-HCL pH 7,5, 1 mM EDTA and 0,1 mM PMSF). The cells were opened with eight strokes by 2500 rpm using a potter homogenisator. Unbroken cells and nuclei were removed by centrifugation at 600x g for 15 min at 4°C. The supernatant was applied to another centrifugation step at 10000x g for 25 min at 4°C. The supernatant contains the cytoplasmic fraction (C) whereas mitochondria are enriched in the pellet. The mitochondrial fraction (M) was washed two times in isotonic buffer and afterwards applied to SDS Page.</p></sec><sec id="s3-8"><title>Cell viability, apoptosis, and proliferation</title><p>Viability and proliferation of HAF were quantified using the Fluorimetric CellTiter-Blue Cell Viability Assay (Promega, Madison, Wisconsin) and the colorimetric Cell Proliferation BrdU-ELISA (Roche Diagnostics, Rotkreuz, Switzerland), respectively, according to the manufacturer´s instructions. Apoptosis of HAF following treatment with staurosporine (Cell signaling, Cambridge, United Kingdom) was determined through quantification of cleaved PARP protein levels on Western blots.</p></sec><sec id="s3-9"><title>Mitochondrial respiratory chain enzyme activity</title><p>Mitochondrial respiratory chain enzyme activities were measured in skin fibroblasts according to established procedures (<xref ref-type="bibr" rid="bib19">Janssen et al., 2006</xref>; <xref ref-type="bibr" rid="bib36">Smeitink et al., 2001</xref>). The values were expressed relative to the activity of Cytochrome C oxidase and/or Citrate synthase.</p></sec><sec id="s3-10"><title>Overexpression of human <italic>YME1L1</italic></title><p>Human wild type <italic>YME1L1</italic> and mutant <italic>YME1L1<sup>R149W</sup></italic> were stably expressed in Flp-In T-Rex HEK293T cells (Life Technologies) under the control of a tetracycline-regulated promotor according to manufacturer´s instructions. HEK293T cells were cultured as described previously (<xref ref-type="bibr" rid="bib31">Potting et al., 2013</xref>). Transient transfection was performed using GeneJuice (EMD Millipore, Darmstadt, Germany) according to manufacturer´s instruction.</p></sec><sec id="s3-11"><title>Sucrose gradient density centrifugation</title><p>Cells were harvested and washed three times in PBS. Subsequently, the cells were resuspended in isotonic buffer (0,25 M Sucrose, 5 mM Tris-HCL pH 7,5, 1 mM EDTA and 1X cOmplete, EDTA-free Protease Inhibitor Cocktail [Sigma]). The cells were opened with 15 strokes by 1000 rpm using a Potter S homogenisator (Sartorius, Göttingen, Germany). Unbroken cells and nuclei were removed by centrifugation at 600x g for 5 min at 4°C. The supernatant was applied to another centrifugation step at 10000x g for 10 min at 4°C. The mitochondrial-enriched membrane fraction (pellet) was re-suspended in lysis buffer (270 mM sucrose, 100 mM KCl, 20 mM 20 mM MgCl<sub>2</sub>, 10 mM Tris/HCl, pH 7.5, and 1X cOmplete, EDTA-free Protease Inhibitor Cocktail) containing 6 g of digitonin per g of protein at a concentration of 2.5 mg/ml for 20 min on ice. Supernatant from a clarifying centrifugation at 16,000 g for 10 min at 4°C was directly applied to a 5–25% sucrose gradient prepared using an automated gradient maker (Biocomp instruments, Fredericton, Canada) in 14x89mm Ultra-Clear centrifuge tubes (Beckman Instruments, Brea, California). Ultracentrifugation was performed at 71,000 x g for 16 hr at 4°C and 1.2 ml fractions (n=10) were collected by hand, precipitated by TCA and subjected to SDS-PAGE.</p></sec><sec id="s3-12"><title>Cell-free synthesis of YME1L1 and processing by purified MPP in vitro</title><p>The cell-free synthesis of (<xref ref-type="bibr" rid="bib2">Baker et al., 2014</xref>) S-labeled precursor proteins of human wild type and mutant YME1L1 was performed using the TNT Sp6 or Coupled Reticulocyte lysate system (Promega) according to the manufacturer's instructions. Radiolabeled wild type and mutant YME1L1 were incubated in cleavage buffer (20 mM HEPES, pH 7,4, 50 mM NaCl<sub>2</sub>, 1 mM Zn Cl<sub>2</sub>, 1 mM ATP, 5 mM Mg Cl<sub>2</sub>) at 30°C in the presence of absence of MPP as described previously (<xref ref-type="bibr" rid="bib27">Nolden et al., 2005</xref>). Samples were analyzed by SDS-PAGE and autoradiography.</p></sec><sec id="s3-13"><title>Immunocytochemistry</title><p>Immunocytochemistry was performed as described previously (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib18">Issa et al., 2013</xref>). Antibodies are listed in <xref ref-type="supplementary-material" rid="SD7-data">Supplementary file 1B</xref>; DAPI was purchased from Sigma-Aldrich.</p></sec><sec id="s3-14"><title>Mitochondrial network analysis</title><p>HAF, MEF, and ACF were stained with anti-TOMM20 antibody and DAPI (4′,6-Diamidin-2-phenylindol). Images were taken as described below and quantified in double-blind fashion into four categories: hyperfused, tubular, short tubules and fragmented mitochondrial network as previously described (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>). For the complementation experiments: co-transfection of 100 ng of mitochondrially-targeted GFP (mito-GFP) along with 1 µg of either YME1L1 or YME1L1<sup>R149W</sup> was performed, and GFP-positive fixed cells were scored for mitochondrial morphology.</p></sec><sec id="s3-15"><title>Imaging</title><p>Fluorescently labeled fibroblasts were imaged with a fluorescent Olympus BX51 microscope using the software Magnafire 2.1B Version 2001 (Olympus, Tokyo, Japan) and a Spinning Disc Microscopy system (Carl Zeiss Microscopy, Oberkochen, Germany) with the ZEN 2012 Software, with an lsm5exciter Zeiss confocal microscope (Carl Zeiss Microscopy). Analysis of overexpression experiment of human wildtype and mutant <italic>YME1L1</italic> was realized with an UltraVIEW VoX spinning disc Yokogawa CSU-X1 confocal microscope (PerkinElmer, Waltham, Massachusetts) on a Nikon Ti microscope equipped with a 60x (Apo TIRF 60x Oil N.A. 1.49) objective and camera (EMCCD C9100-50 CamLink). Imaging of HeLa cells was performed using a Meta 510 confocal laser scanning microscope (Carl Zeiss). All images were processed using Adobe Photoshop (Adobe Systems Inc., San José, California), Volocity (PerkinElmer), and ImageJ (National Institute of Health, USA).</p></sec><sec id="s3-16"><title>Live-cell imaging</title><p>HAF were cultured on 35 mm Fluorodish Cell Culture Dishes (World Precision Instruments, Sarasota, Florida) and incubated in pre-warmed medium containing 500 nM MitoTracker Green (Thermo Fisher Scientific, Waltham, Massachusetts) 30 min prior to imaging. Live-cell imaging was performed in fresh medium in the microscope incubation chamber (5% CO<sub>2</sub>, 37°C) of a Zeiss Axio Observer with Spinning Disc Technology Carl Zeiss Microscopy) for 7–10 min. Recordings were processed using Adobe Photoshop (Adobe Systems Inc.) and Magix Video Maker Deluxe (Magix Software GmbH, Berlin, Germany).</p></sec><sec id="s3-17"><title>Electron microscopy (EM)</title><p>Fibroblasts and muscle biopsy specimen were prepared for TEM analysis and imaged as described previously (<xref ref-type="bibr" rid="bib1">Anand et al., 2014</xref>; <xref ref-type="bibr" rid="bib38">Stenzel et al., 2015</xref>; <xref ref-type="bibr" rid="bib45">Wakabayashi et al., 2009</xref>).</p></sec><sec id="s3-18"><title>Statistical methods</title><p>All results are presented as mean ± SD, GraphPad Prism 5 software was used for all statistical analyses, and the significance level was set at p&lt;0.05. Differences between two groups were evaluated by un-paired or paired Student’s t-test, while for multi-group comparisons, one-way ANOVA with Tukey’s multiple-comparison test was used. For the mitochondrial fragmentation analysis (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), two-way ANOVA followed by the Tukey’s multiple-comparisons test was used. Sample sizes, replicate numbers, and p-values are stated in the figure legends. Replicates are biological replicates except for experiments illustrated in <xref ref-type="fig" rid="fig1">Figures 1H</xref> and <xref ref-type="fig" rid="fig2">2B</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors thank the family members who participated in this study. We acknowledge T. Burmester for sending us fibroblasts of the affected children, E. Morava-Kozicz, D. Emmerich for sending DNA samples of patients with YME1L1 mitochondriopathy-like phenotypes, as well as G. Stoltenburg-Didinger, V. Tarabykin, C. Birchmeier, N. Krämer, K. Voigt, and J. Fassbender for technical help and discussions. This work was supported by the German Research Foundation (SFB665, KO2891/1-1, Reinhart Koselleck grant), the Berlin Institute of Health (BIH, CRG1), the Sonnenfeld Stiftung, the German Society for Muscle diseases (DGM), the German Academic Exchange Service (DAAD), the NCRR P20-RR016453, the Robert C. Perry Fund (20061479), the Max-Planck Society, the EU FP 7 project GENCODYS (241995), and the Human Frontiers Science Program.</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>BH, Conception and design, Performed functional experiments, Analysis and interpretation of data, Drafted the manuscript</p></fn><fn fn-type="con" id="con2"><p>TW, Conception and design, Performed functional experiments, Analysis and interpretation of data, Drafted the manuscript</p></fn><fn fn-type="con" id="con3"><p>HH, Generated and analyzed WES and performed further mutation analyses in the cohort, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>TM, Performed functional experiments, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>LM, Generated and analyzed WES and performed further mutation analyses in the cohort, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>BF-Z, Performed functional experiments, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>WS, Acquisition of data, Aanalyzed patient muscle specimen, Drafting or revising the article</p></fn><fn fn-type="con" id="con8"><p>RG, Helped with imaging, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con9"><p>LvdH, Performed mitochondrial enzyme studies and related DNA studies, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con10"><p>H-HR, Conception and design, Generated and analyzed WES and performed further mutation analyses in the cohort, Drafting or revising the article</p></fn><fn fn-type="con" id="con11"><p>TFW, Conception and design, Generated and analyzed WES and performed further mutation analyses in the cohort, Drafting or revising the article</p></fn><fn fn-type="con" id="con12"><p>CH, Conception and design, Recruited subjects, Gathered patient history as well as clinical information, Contributed clinical samples, Drafting or revising the article</p></fn><fn fn-type="con" id="con13"><p>TL, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafted the article</p></fn><fn fn-type="con" id="con14"><p>AMK, Conception and design, Recruited subjects, Gathered patient history as well as clinical information, Contributed clinical samples, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other" id="fn1"><p>Human subjects: Informed consent was obtained from the parents of the patients for the molecular genetic analysis, the publication of clinical data, photos, magnetic resonance images (MRI), and studies on fibroblasts. The human study was approved by the local ethics committee of the Charité (approval no. EA½12/08).</p></fn><fn fn-type="other" id="fn2"><p>Animal experimentation: All animal experiments were carried out in accordance to the national ethic principles (registration no. T0344/12, Charité).</p></fn></fn-group></sec><sec id="s5" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="SD7-data"><object-id pub-id-type="doi">10.7554/eLife.16078.019</object-id><label>Supplementary file 1.</label><caption><title>List of primers and antibodies.</title><p>(A) List of primers for qPCR and genotyping. (B) List of primary and secondary antibodies.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.16078.019">http://dx.doi.org/10.7554/eLife.16078.019</ext-link></p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-16078-supp1-v2.docx"/></supplementary-material><sec id="s6" sec-type="datasets"><title>Major datasets</title><p>The following dataset was generated:</p><p><related-object content-type="generated-dataset" id="data-ro1" source-id="http://www.ncbi.nlm.nih.gov/gquery/?term=SRP073309" source-id-type="uri"><collab>Hartmann B</collab><x>,</x> <collab>Wai T</collab><x>,</x> <collab>Hao Hu</collab><x>,</x> <collab>MacVicar T</collab><x>,</x> <collab>Musante L</collab><x>,</x> <collab>Fischer-Zirnsak B</collab><x>,</x> <collab>Stenzel W</collab><x>,</x> <collab>Graef R</collab><x>,</x> <collab>van den Heuvel L</collab><x>,</x> <collab>Ropers HH</collab><x>,</x> <collab>Wienker TF</collab><x>,</x> <collab>Hübner C</collab><x>,</x> <collab>Langer T</collab><x>,</x> <collab>Kaindl AM</collab><x>,</x> <year>2016</year><x>,</x><source>Homozygous YME1L1 mutation causes mitochondriopathy with optic atrophy and mitochondrial network fragmentation</source><x>,</x> <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/gquery/?term=SRP073309">http://www.ncbi.nlm.nih.gov/gquery/?term=SRP073309</ext-link><x>,</x> <comment>Publicly available at the NCBI Gene Expression Omnibus (accession no: SRP073309)</comment></related-object></p></sec></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Wai</surname><given-names>T</given-names></name><name><surname>Baker</surname><given-names>MJ</given-names></name><name><surname>Kladt</surname><given-names>N</given-names></name><name><surname>Schauss</surname><given-names>AC</given-names></name><name><surname>Rugarli</surname><given-names>E</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The i-AAA protease YME1L and OMA1 cleave OPA1 to balance mitochondrial fusion and fission</article-title><source>The Journal of Cell Biology</source><volume>204</volume><fpage>919</fpage><lpage>929</lpage><pub-id pub-id-type="doi">10.1083/jcb.201308006</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MJ</given-names></name><name><surname>Lampe</surname><given-names>PA</given-names></name><name><surname>Stojanovski</surname><given-names>D</given-names></name><name><surname>Korwitz</surname><given-names>A</given-names></name><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Tatsuta</surname><given-names>T</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Stress-induced OMA1 activation and autocatalytic turnover regulate OPA1-dependent mitochondrial dynamics</article-title><source>The EMBO Journal</source><volume>33</volume><fpage>578</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1002/embj.201386474</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>MJ</given-names></name><name><surname>Mooga</surname><given-names>VP</given-names></name><name><surname>Guiard</surname><given-names>B</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name><name><surname>Ryan</surname><given-names>MT</given-names></name><name><surname>Stojanovski</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Impaired folding of the mitochondrial small TIM chaperones induces clearance by the i-AAA protease</article-title><source>Journal of Molecular Biology</source><volume>424</volume><fpage>227</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2012.09.019</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burté</surname><given-names>F</given-names></name><name><surname>Carelli</surname><given-names>V</given-names></name><name><surname>Chinnery</surname><given-names>PF</given-names></name><name><surname>Yu-Wai-Man</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Disturbed mitochondrial dynamics and neurodegenerative disorders</article-title><source>Nature Reviews Neurology</source><volume>11</volume><fpage>11</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/nrneurol.2014.228</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>CL</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><name><surname>White</surname><given-names>KH</given-names></name><name><surname>Thorsness</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Mitochondrial morphological and functional defects in yeast caused by yme1 are suppressed by mutation of a 26S protease subunit homologue</article-title><source>Molecular Biology of the Cell</source><volume>5</volume><fpage>899</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1091/mbc.5.8.899</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Martins de Brito</surname><given-names>O</given-names></name><name><surname>Dal Zilio</surname><given-names>B</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>OPA1 requires mitofusin 1 to promote mitochondrial fusion</article-title><source>PNAS</source><volume>101</volume><fpage>15927</fpage><lpage>15932</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407043101</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Claros</surname><given-names>MG</given-names></name><name><surname>Vincens</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Computational method to predict mitochondrially imported proteins and their targeting sequences</article-title><source>European Journal of Biochemistry</source><volume>241</volume><fpage>779</fpage><lpage>786</lpage><pub-id pub-id-type="doi">10.1111/j.1432-1033.1996.00779.x</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coenen</surname><given-names>MJ</given-names></name><name><surname>Smeitink</surname><given-names>JA</given-names></name><name><surname>Smeets</surname><given-names>R</given-names></name><name><surname>Trijbels</surname><given-names>FJ</given-names></name><name><surname>van den Heuvel</surname><given-names>LP</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Mutation detection in four candidate genes (OXA1L, MRS2L, YME1L and MIPEP) for combined deficiencies in the oxidative phosphorylation system</article-title><source>Journal of Inherited Metabolic Disease</source><volume>28</volume><fpage>1091</fpage><lpage>1097</lpage><pub-id pub-id-type="doi">10.1007/s10545-005-4483-y</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cong</surname><given-names>L</given-names></name><name><surname>Ran</surname><given-names>FA</given-names></name><name><surname>Cox</surname><given-names>D</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Barretto</surname><given-names>R</given-names></name><name><surname>Habib</surname><given-names>N</given-names></name><name><surname>Hsu</surname><given-names>PD</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Marraffini</surname><given-names>LA</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Multiplex genome engineering using CRISPR/Cas systems</article-title><source>Science</source><volume>339</volume><fpage>819</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1126/science.1231143</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Michele</surname><given-names>G</given-names></name><name><surname>De Fusco</surname><given-names>M</given-names></name><name><surname>Cavalcanti</surname><given-names>F</given-names></name><name><surname>Filla</surname><given-names>A</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Volpe</surname><given-names>G</given-names></name><name><surname>Monticelli</surname><given-names>A</given-names></name><name><surname>Ballabio</surname><given-names>A</given-names></name><name><surname>Casari</surname><given-names>G</given-names></name><name><surname>Cocozza</surname><given-names>S</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A new locus for autosomal recessive hereditary spastic paraplegia maps to chromosome 16q24.3</article-title><source>The American Journal of Human Genetics</source><volume>63</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1086/301930</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delettre</surname><given-names>C</given-names></name><name><surname>Lenaers</surname><given-names>G</given-names></name><name><surname>Griffoin</surname><given-names>JM</given-names></name><name><surname>Gigarel</surname><given-names>N</given-names></name><name><surname>Lorenzo</surname><given-names>C</given-names></name><name><surname>Belenguer</surname><given-names>P</given-names></name><name><surname>Pelloquin</surname><given-names>L</given-names></name><name><surname>Grosgeorge</surname><given-names>J</given-names></name><name><surname>Turc-Carel</surname><given-names>C</given-names></name><name><surname>Perret</surname><given-names>E</given-names></name><name><surname>Astarie-Dequeker</surname><given-names>C</given-names></name><name><surname>Lasquellec</surname><given-names>L</given-names></name><name><surname>Arnaud</surname><given-names>B</given-names></name><name><surname>Ducommun</surname><given-names>B</given-names></name><name><surname>Kaplan</surname><given-names>J</given-names></name><name><surname>Hamel</surname><given-names>CP</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy</article-title><source>Nature Genetics</source><volume>26</volume><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1038/79936</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehses</surname><given-names>S</given-names></name><name><surname>Raschke</surname><given-names>I</given-names></name><name><surname>Mancuso</surname><given-names>G</given-names></name><name><surname>Bernacchia</surname><given-names>A</given-names></name><name><surname>Geimer</surname><given-names>S</given-names></name><name><surname>Tondera</surname><given-names>D</given-names></name><name><surname>Martinou</surname><given-names>JC</given-names></name><name><surname>Westermann</surname><given-names>B</given-names></name><name><surname>Rugarli</surname><given-names>EI</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Regulation of OPA1 processing and mitochondrial fusion by m-AAA protease isoenzymes and OMA1</article-title><source>The Journal of Cell Biology</source><volume>187</volume><fpage>1023</fpage><lpage>1036</lpage><pub-id pub-id-type="doi">10.1083/jcb.200906084</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Martins de Brito</surname><given-names>O</given-names></name><name><surname>Micaroni</surname><given-names>M</given-names></name><name><surname>Beznoussenko</surname><given-names>GV</given-names></name><name><surname>Rudka</surname><given-names>T</given-names></name><name><surname>Bartoli</surname><given-names>D</given-names></name><name><surname>Polishuck</surname><given-names>RS</given-names></name><name><surname>Danial</surname><given-names>NN</given-names></name><name><surname>De Strooper</surname><given-names>B</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion</article-title><source>Cell</source><volume>126</volume><fpage>177</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.06.025</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Graef</surname><given-names>M</given-names></name><name><surname>Seewald</surname><given-names>G</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Substrate recognition by AAA+ ATPases: distinct substrate binding modes in ATP-dependent protease Yme1 of the mitochondrial intermembrane space</article-title><source>Molecular and Cellular Biology</source><volume>27</volume><fpage>2476</fpage><lpage>2485</lpage><pub-id pub-id-type="doi">10.1128/MCB.01721-06</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griparic</surname><given-names>L</given-names></name><name><surname>Kanazawa</surname><given-names>T</given-names></name><name><surname>van der Bliek</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Regulation of the mitochondrial dynamin-like protein Opa1 by proteolytic cleavage</article-title><source>The Journal of Cell Biology</source><volume>178</volume><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1083/jcb.200704112</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hazan</surname><given-names>J</given-names></name><name><surname>Fontaine</surname><given-names>B</given-names></name><name><surname>Bruyn</surname><given-names>RP</given-names></name><name><surname>Lamy</surname><given-names>C</given-names></name><name><surname>van Deutekom</surname><given-names>JC</given-names></name><name><surname>Rime</surname><given-names>CS</given-names></name><name><surname>Dürr</surname><given-names>A</given-names></name><name><surname>Melki</surname><given-names>J</given-names></name><name><surname>Lyon-Caen</surname><given-names>O</given-names></name><name><surname>Agid</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p</article-title><source>Human Molecular Genetics</source><volume>3</volume><fpage>1569</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1093/hmg/3.9.1569</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Head</surname><given-names>B</given-names></name><name><surname>Griparic</surname><given-names>L</given-names></name><name><surname>Amiri</surname><given-names>M</given-names></name><name><surname>Gandre-Babbe</surname><given-names>S</given-names></name><name><surname>van der Bliek</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Inducible proteolytic inactivation of OPA1 mediated by the OMA1 protease in mammalian cells</article-title><source>The Journal of Cell Biology</source><volume>187</volume><fpage>959</fpage><lpage>966</lpage><pub-id pub-id-type="doi">10.1083/jcb.200906083</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Issa</surname><given-names>L</given-names></name><name><surname>Kraemer</surname><given-names>N</given-names></name><name><surname>Rickert</surname><given-names>CH</given-names></name><name><surname>Sifringer</surname><given-names>M</given-names></name><name><surname>Ninnemann</surname><given-names>O</given-names></name><name><surname>Stoltenburg-Didinger</surname><given-names>G</given-names></name><name><surname>Kaindl</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>CDK5RAP2 expression during murine and human brain development correlates with pathology in primary autosomal recessive microcephaly</article-title><source>Cerebral Cortex</source><volume>23</volume><fpage>2245</fpage><lpage>2260</lpage><pub-id pub-id-type="doi">10.1093/cercor/bhs212</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssen</surname><given-names>AJ</given-names></name><name><surname>Trijbels</surname><given-names>FJ</given-names></name><name><surname>Sengers</surname><given-names>RC</given-names></name><name><surname>Wintjes</surname><given-names>LT</given-names></name><name><surname>Ruitenbeek</surname><given-names>W</given-names></name><name><surname>Smeitink</surname><given-names>JA</given-names></name><name><surname>Morava</surname><given-names>E</given-names></name><name><surname>van Engelen</surname><given-names>BG</given-names></name><name><surname>van den Heuvel</surname><given-names>LP</given-names></name><name><surname>Rodenburg</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Measurement of the energy-generating capacity of human muscle mitochondria: diagnostic procedure and application to human pathology</article-title><source>Clinical Chemistry</source><volume>52</volume><fpage>860</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2005.062414</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korwitz</surname><given-names>A</given-names></name><name><surname>Merkwirth</surname><given-names>C</given-names></name><name><surname>Richter-Dennerlein</surname><given-names>R</given-names></name><name><surname>Tröder</surname><given-names>SE</given-names></name><name><surname>Sprenger</surname><given-names>HG</given-names></name><name><surname>Quirós</surname><given-names>PM</given-names></name><name><surname>López-Otín</surname><given-names>C</given-names></name><name><surname>Rugarli</surname><given-names>EI</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Loss of OMA1 delays neurodegeneration by preventing stress-induced OPA1 processing in mitochondria</article-title><source>The Journal of Cell Biology</source><volume>212</volume><fpage>157</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1083/jcb.201507022</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonhard</surname><given-names>K</given-names></name><name><surname>Herrmann</surname><given-names>JM</given-names></name><name><surname>Stuart</surname><given-names>RA</given-names></name><name><surname>Mannhaupt</surname><given-names>G</given-names></name><name><surname>Neupert</surname><given-names>W</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>AAA proteases with catalytic sites on opposite membrane surfaces comprise a proteolytic system for the ATP-dependent degradation of inner membrane proteins in mitochondria</article-title><source>The EMBO Journal</source><volume>15</volume><fpage>4218</fpage><lpage>4229</lpage></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacVicar</surname><given-names>T</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>OPA1 processing in cell death and disease - the long and short of it</article-title><source>Journal of Cell Science</source><volume>129</volume><fpage>2297</fpage><lpage>2306</lpage><pub-id pub-id-type="doi">10.1242/jcs.159186</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Najmabadi</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Garshasbi</surname><given-names>M</given-names></name><name><surname>Zemojtel</surname><given-names>T</given-names></name><name><surname>Abedini</surname><given-names>SS</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Hosseini</surname><given-names>M</given-names></name><name><surname>Behjati</surname><given-names>F</given-names></name><name><surname>Haas</surname><given-names>S</given-names></name><name><surname>Jamali</surname><given-names>P</given-names></name><name><surname>Zecha</surname><given-names>A</given-names></name><name><surname>Mohseni</surname><given-names>M</given-names></name><name><surname>Püttmann</surname><given-names>L</given-names></name><name><surname>Vahid</surname><given-names>LN</given-names></name><name><surname>Jensen</surname><given-names>C</given-names></name><name><surname>Moheb</surname><given-names>LA</given-names></name><name><surname>Bienek</surname><given-names>M</given-names></name><name><surname>Larti</surname><given-names>F</given-names></name><name><surname>Mueller</surname><given-names>I</given-names></name><name><surname>Weissmann</surname><given-names>R</given-names></name><name><surname>Darvish</surname><given-names>H</given-names></name><name><surname>Wrogemann</surname><given-names>K</given-names></name><name><surname>Hadavi</surname><given-names>V</given-names></name><name><surname>Lipkowitz</surname><given-names>B</given-names></name><name><surname>Esmaeeli-Nieh</surname><given-names>S</given-names></name><name><surname>Wieczorek</surname><given-names>D</given-names></name><name><surname>Kariminejad</surname><given-names>R</given-names></name><name><surname>Firouzabadi</surname><given-names>SG</given-names></name><name><surname>Cohen</surname><given-names>M</given-names></name><name><surname>Fattahi</surname><given-names>Z</given-names></name><name><surname>Rost</surname><given-names>I</given-names></name><name><surname>Mojahedi</surname><given-names>F</given-names></name><name><surname>Hertzberg</surname><given-names>C</given-names></name><name><surname>Dehghan</surname><given-names>A</given-names></name><name><surname>Rajab</surname><given-names>A</given-names></name><name><surname>Banavandi</surname><given-names>MJ</given-names></name><name><surname>Hoffer</surname><given-names>J</given-names></name><name><surname>Falah</surname><given-names>M</given-names></name><name><surname>Musante</surname><given-names>L</given-names></name><name><surname>Kalscheuer</surname><given-names>V</given-names></name><name><surname>Ullmann</surname><given-names>R</given-names></name><name><surname>Kuss</surname><given-names>AW</given-names></name><name><surname>Tzschach</surname><given-names>A</given-names></name><name><surname>Kahrizi</surname><given-names>K</given-names></name><name><surname>Ropers</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Deep sequencing reveals 50 novel genes for recessive cognitive disorders</article-title><source>Nature</source><volume>478</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/nature10423</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakai</surname><given-names>T</given-names></name><name><surname>Yasuhara</surname><given-names>T</given-names></name><name><surname>Fujiki</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Multiple genes, including a member of the AAA family, are essential for degradation of unassembled subunit 2 of cytochrome c oxidase in yeast mitochondria</article-title><source>Molecular and Cellular Biology</source><volume>15</volume><fpage>4441</fpage><lpage>4452</lpage><pub-id pub-id-type="doi">10.1128/MCB.15.8.4441</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>JE</given-names></name><name><surname>Koefoed</surname><given-names>P</given-names></name><name><surname>Abell</surname><given-names>K</given-names></name><name><surname>Hasholt</surname><given-names>L</given-names></name><name><surname>Eiberg</surname><given-names>H</given-names></name><name><surname>Fenger</surname><given-names>K</given-names></name><name><surname>Niebuhr</surname><given-names>E</given-names></name><name><surname>Sørensen</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>CAG repeat expansion in autosomal dominant pure spastic paraplegia linked to chromosome 2p21-p24</article-title><source>Human Molecular Genetics</source><volume>6</volume><fpage>1811</fpage><lpage>1816</lpage><pub-id pub-id-type="doi">10.1093/hmg/6.11.1811</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niidome</surname><given-names>T</given-names></name><name><surname>Kitada</surname><given-names>S</given-names></name><name><surname>Shimokata</surname><given-names>K</given-names></name><name><surname>Ogishima</surname><given-names>T</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Arginine residues in the extension peptide are required for cleavage of a precursor by mitochondrial processing peptidase. Demonstration using synthetic peptide as a substrate</article-title><source>The Journal of Biological Chemistry</source><volume>269</volume><fpage>24719</fpage><lpage>24722</lpage></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolden</surname><given-names>M</given-names></name><name><surname>Ehses</surname><given-names>S</given-names></name><name><surname>Koppen</surname><given-names>M</given-names></name><name><surname>Bernacchia</surname><given-names>A</given-names></name><name><surname>Rugarli</surname><given-names>EI</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>The m-AAA protease defective in hereditary spastic paraplegia controls ribosome assembly in mitochondria</article-title><source>Cell</source><volume>123</volume><fpage>277</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2005.08.003</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nunnari</surname><given-names>J</given-names></name><name><surname>Suomalainen</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Mitochondria: in sickness and in health</article-title><source>Cell</source><volume>148</volume><fpage>1145</fpage><lpage>1159</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.035</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olichon</surname><given-names>A</given-names></name><name><surname>Baricault</surname><given-names>L</given-names></name><name><surname>Gas</surname><given-names>N</given-names></name><name><surname>Guillou</surname><given-names>E</given-names></name><name><surname>Valette</surname><given-names>A</given-names></name><name><surname>Belenguer</surname><given-names>P</given-names></name><name><surname>Lenaers</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Loss of OPA1 perturbates the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>7743</fpage><lpage>7746</lpage><pub-id pub-id-type="doi">10.1074/jbc.C200677200</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>DA</given-names></name><name><surname>Sherman</surname><given-names>F</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Degradation of cytochrome oxidase subunits in mutants of yeast lacking cytochrome c and suppression of the degradation by mutation of yme1</article-title><source>Journal of Biological Chemistry</source><volume>270</volume><fpage>20879</fpage><lpage>20882</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.36.20879</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Potting</surname><given-names>C</given-names></name><name><surname>Tatsuta</surname><given-names>T</given-names></name><name><surname>König</surname><given-names>T</given-names></name><name><surname>Haag</surname><given-names>M</given-names></name><name><surname>Wai</surname><given-names>T</given-names></name><name><surname>Aaltonen</surname><given-names>MJ</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>TRIAP1/PRELI complexes prevent apoptosis by mediating intramitochondrial transport of phosphatidic acid</article-title><source>Cell Metabolism</source><volume>18</volume><fpage>287</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2013.07.008</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainbolt</surname><given-names>TK</given-names></name><name><surname>Lebeau</surname><given-names>J</given-names></name><name><surname>Puchades</surname><given-names>C</given-names></name><name><surname>Wiseman</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Reciprocal Degradation of YME1L and OMA1 Adapts Mitochondrial Proteolytic Activity during Stress</article-title><source>Cell Reports</source><volume>14</volume><fpage>2041</fpage><lpage>2049</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.02.011</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainbolt</surname><given-names>TK</given-names></name><name><surname>Saunders</surname><given-names>JM</given-names></name><name><surname>Wiseman</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>YME1L degradation reduces mitochondrial proteolytic capacity during oxidative stress</article-title><source>EMBO Reports</source><volume>16</volume><fpage>97</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.15252/embr.201438976</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rainey</surname><given-names>RN</given-names></name><name><surname>Glavin</surname><given-names>JD</given-names></name><name><surname>Chen</surname><given-names>HW</given-names></name><name><surname>French</surname><given-names>SW</given-names></name><name><surname>Teitell</surname><given-names>MA</given-names></name><name><surname>Koehler</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>A new function in translocation for the mitochondrial i-AAA protease Yme1: import of polynucleotide phosphorylase into the intermembrane space</article-title><source>Molecular and Cellular Biology</source><volume>26</volume><fpage>8488</fpage><lpage>8497</lpage><pub-id pub-id-type="doi">10.1128/MCB.01006-06</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shah</surname><given-names>ZH</given-names></name><name><surname>Hakkaart</surname><given-names>GA</given-names></name><name><surname>Arku</surname><given-names>B</given-names></name><name><surname>de Jong</surname><given-names>L</given-names></name><name><surname>van der Spek</surname><given-names>H</given-names></name><name><surname>Grivell</surname><given-names>LA</given-names></name><name><surname>Jacobs</surname><given-names>HT</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The human homologue of the yeast mitochondrial AAA metalloprotease Yme1p complements a yeast yme1 disruptant</article-title><source>FEBS Letters</source><volume>478</volume><fpage>267</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(00)01859-7</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smeitink</surname><given-names>J</given-names></name><name><surname>Sengers</surname><given-names>R</given-names></name><name><surname>Trijbels</surname><given-names>F</given-names></name><name><surname>van den Heuvel</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Human NADH:ubiquinone oxidoreductase</article-title><source>Journal of Bioenergetics and Biomembranes</source><volume>33</volume><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1023/A:1010743321800</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fiket</surname><given-names>M</given-names></name><name><surname>Alexander</surname><given-names>C</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>OPA1 processing controls mitochondrial fusion and is regulated by mRNA splicing, membrane potential, and Yme1L</article-title><source>The Journal of Cell Biology</source><volume>178</volume><fpage>749</fpage><lpage>755</lpage><pub-id pub-id-type="doi">10.1083/jcb.200704110</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenzel</surname><given-names>W</given-names></name><name><surname>Preuße</surname><given-names>C</given-names></name><name><surname>Allenbach</surname><given-names>Y</given-names></name><name><surname>Pehl</surname><given-names>D</given-names></name><name><surname>Junckerstorff</surname><given-names>R</given-names></name><name><surname>Heppner</surname><given-names>FL</given-names></name><name><surname>Nolte</surname><given-names>K</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name><name><surname>Kana</surname><given-names>V</given-names></name><name><surname>Rushing</surname><given-names>E</given-names></name><name><surname>Schneider</surname><given-names>U</given-names></name><name><surname>Claeys</surname><given-names>KG</given-names></name><name><surname>Benveniste</surname><given-names>O</given-names></name><name><surname>Weis</surname><given-names>J</given-names></name><name><surname>Goebel</surname><given-names>HH</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nuclear actin aggregation is a hallmark of anti-synthetase syndrome-induced dysimmune myopathy</article-title><source>Neurology</source><volume>84</volume><fpage>1346</fpage><lpage>1354</lpage><pub-id pub-id-type="doi">10.1212/WNL.0000000000001422</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stiburek</surname><given-names>L</given-names></name><name><surname>Cesnekova</surname><given-names>J</given-names></name><name><surname>Kostkova</surname><given-names>O</given-names></name><name><surname>Fornuskova</surname><given-names>D</given-names></name><name><surname>Vinsova</surname><given-names>K</given-names></name><name><surname>Wenchich</surname><given-names>L</given-names></name><name><surname>Houstek</surname><given-names>J</given-names></name><name><surname>Zeman</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>YME1L controls the accumulation of respiratory chain subunits and is required for apoptotic resistance, cristae morphogenesis, and cell proliferation</article-title><source>Molecular Biology of the Cell</source><volume>23</volume><fpage>1010</fpage><lpage>1023</lpage><pub-id pub-id-type="doi">10.1091/mbc.E11-08-0674</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorsness</surname><given-names>PE</given-names></name><name><surname>White</surname><given-names>KH</given-names></name><name><surname>Fox</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Inactivation of YME1, a member of the ftsH-SEC18-PAS1-CDC48 family of putative ATPase-encoding genes, causes increased escape of DNA from mitochondria in Saccharomyces cerevisiae</article-title><source>Molecular and Cellular Biology</source><volume>13</volume><fpage>5418</fpage><lpage>5426</lpage><pub-id pub-id-type="doi">10.1128/MCB.13.9.5418</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Bliek</surname><given-names>AM</given-names></name><name><surname>Koehler</surname><given-names>CM</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>A mitochondrial rhomboid protease</article-title><source>Developmental Cell</source><volume>4</volume><fpage>769</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1016/S1534-5807(03)00167-9</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Dyck</surname><given-names>L</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>ATP-dependent proteases controlling mitochondrial function in the yeast Saccharomyces cerevisiae</article-title><source>Cellular and Molecular Life Sciences</source><volume>56</volume><fpage>825</fpage><lpage>842</lpage><pub-id pub-id-type="doi">10.1007/s000180050029</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogel</surname><given-names>RO</given-names></name><name><surname>Janssen</surname><given-names>RJ</given-names></name><name><surname>Ugalde</surname><given-names>C</given-names></name><name><surname>Grovenstein</surname><given-names>M</given-names></name><name><surname>Huijbens</surname><given-names>RJ</given-names></name><name><surname>Visch</surname><given-names>HJ</given-names></name><name><surname>van den Heuvel</surname><given-names>LP</given-names></name><name><surname>Willems</surname><given-names>PH</given-names></name><name><surname>Zeviani</surname><given-names>M</given-names></name><name><surname>Smeitink</surname><given-names>JA</given-names></name><name><surname>Nijtmans</surname><given-names>LG</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Human mitochondrial complex I assembly is mediated by NDUFAF1</article-title><source>FEBS Journal</source><volume>272</volume><fpage>5317</fpage><lpage>5326</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2005.04928.x</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wai</surname><given-names>T</given-names></name><name><surname>García-Prieto</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>MJ</given-names></name><name><surname>Merkwirth</surname><given-names>C</given-names></name><name><surname>Benit</surname><given-names>P</given-names></name><name><surname>Rustin</surname><given-names>P</given-names></name><name><surname>Rupérez</surname><given-names>FJ</given-names></name><name><surname>Barbas</surname><given-names>C</given-names></name><name><surname>Ibañez</surname><given-names>B</given-names></name><name><surname>Langer</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice</article-title><source>Science</source><volume>350</volume><elocation-id>aad0116</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad0116</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakabayashi</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Wakabayashi</surname><given-names>N</given-names></name><name><surname>Tamura</surname><given-names>Y</given-names></name><name><surname>Fukaya</surname><given-names>M</given-names></name><name><surname>Kensler</surname><given-names>TW</given-names></name><name><surname>Iijima</surname><given-names>M</given-names></name><name><surname>Sesaki</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The dynamin-related GTPase Drp1 is required for embryonic and brain development in mice</article-title><source>The Journal of Cell Biology</source><volume>186</volume><fpage>805</fpage><lpage>816</lpage><pub-id pub-id-type="doi">10.1083/jcb.200903065</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warnecke</surname><given-names>T</given-names></name><name><surname>Duning</surname><given-names>T</given-names></name><name><surname>Schwan</surname><given-names>A</given-names></name><name><surname>Lohmann</surname><given-names>H</given-names></name><name><surname>Epplen</surname><given-names>JT</given-names></name><name><surname>Young</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>A novel form of autosomal recessive hereditary spastic paraplegia caused by a new SPG7 mutation</article-title><source>Neurology</source><volume>69</volume><fpage>368</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000266667.91074.fe</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weber</surname><given-names>ER</given-names></name><name><surname>Hanekamp</surname><given-names>T</given-names></name><name><surname>Thorsness</surname><given-names>PE</given-names></name></person-group><year iso-8601-date="1996">1996</year><article-title>Biochemical and functional analysis of the YME1 gene product, an ATP and zinc-dependent mitochondrial protease from S. cerevisiae</article-title><source>Molecular Biology of the Cell</source><volume>7</volume><fpage>307</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.1091/mbc.7.2.307</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Shoubridge</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Expression and functional analysis of SURF1 in Leigh syndrome patients with cytochrome c oxidase deficiency</article-title><source>Human Molecular Genetics</source><volume>8</volume><fpage>2541</fpage><lpage>2549</lpage><pub-id pub-id-type="doi">10.1093/hmg/8.13.2541</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Johns</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>K</given-names></name><name><surname>De Bie</surname><given-names>I</given-names></name><name><surname>Macmillan</surname><given-names>C</given-names></name><name><surname>Cuthbert</surname><given-names>AP</given-names></name><name><surname>Newbold</surname><given-names>RF</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Chevrette</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>GK</given-names></name><name><surname>Brown</surname><given-names>RM</given-names></name><name><surname>Shoubridge</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome</article-title><source>Nature Genetics</source><volume>20</volume><fpage>337</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1038/3804</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.16078.022</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Gleeson</surname><given-names>Joseph G</given-names></name><role>Reviewing editor</role><aff id="aff12"><institution>Howard Hughes Medical Institute, The Rockefeller University</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your article &quot;Homozygous <italic>YME1L1</italic> Mutation Causes Mitochondriopathy with Optic Atrophy and Mitochondrial Network Fragmentation&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Harry Dietz as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.</p><p>Summary:</p><p>In this manuscript, the authors identify a R149W genetic mutation in the mitochondrial inner membrane protease YME1L in patients with many neurologic phenotypes including intellectual disability, motor development delay, optic nerve atrophy, hearing impairment and variations in brain size. In addition, patients presented with other idiosyncratic phenotypes including other neurologic defects. The authors show that this mutation impairs maturation of YME1L by inhibiting processing of the precursor YME1L polypeptide by mitochondrial processing protease (MPP). This impaired processing destabilizes YME1L<sup>R149W</sup> and reduces, but does not completely ablate, YME1L protein levels and activity. The authors then use overexpression to demonstrate that the degradation of precursor YME1L is mediated through an ATP-dependent autocatalytic mechanism. Furthermore, they demonstrate that YME1L<sup>R149W</sup> impairs regulation of mitochondria morphology leading to fragmentation and decreases cell proliferation – both phenotypes observed in YME1L-deficient cells. However, the extent of these phenotypes in YME1L<sup>R149W</sup> expressing patient fibroblasts is less than that observed in YME1L deficient cells, reflecting the residual activity of the mutant. Finally, the authors indicate that YME1L<sup>R149W</sup>-expressing fibroblasts have the same levels of ETC activity as controls, but have lower levels of mitochondria markers, suggesting a reduction in mitochondrial mass. Ultimately, these results demonstrate that reductions in YME1L activity afforded by the R149W YME1L mutation lead to neurologic defects in patients, demonstrating that YME1L activity is clinically important for the maintenance of mitochondrial biology in vivo.</p><p>Essential revisions:</p><p>Additional experiments are required to better characterize the residual YME1L activity observed in YME1L<sup>R149W</sup>-expressing patient fibroblasts. Does this result from a population of mature YME1L that accumulates in this cell or does it result from unprocessed YME1L<sup>R149W</sup> that assembles into the active oligomer? Current data suggests the former, but more characterization of this active YME1L population in these cells is important to explain the more modest phenotypes observed in these cells as compared to YME1L-deficient cells.</p><p>The mechanism of YME1L<sup>R149W</sup> degradation is not clear. It's not clear if YME1L<sup>R149W</sup> is targeted to mitochondria efficiently in the first place or if it is degraded prior to entering mitochondria by other proteases (e.g., the proteasome). More experiments related to this point would be very helpful in further demonstrating exactly how this mutation influences YME1L activity in patient cells.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.16078.023</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>Essential revisions:</italic> </p><p><italic>Additional experiments are required to better characterize the residual YME1L activity observed in YME1L<sup>R149W</sup>-expressing patient fibroblasts. Does this result from a population of mature YME1L that accumulates in this cell or does it result from unprocessed YME1L<sup>R149W</sup> that assembles into the active oligomer? Current data suggests the former, but more characterization of this active YME1L population in these cells is important to explain the more modest phenotypes observed in these cells as compared to YME1L-deficient cells.</italic> </p><p>We have analyzed the ability of the unprocessed precursor form of YME1L1<sup>R149W</sup> to assemble into the active oligomer by sucrose gradient centrifugation (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). To facilitate detection of the precursor form we have additionally introduced a mutation into the ATPase domain of YME1L1 to prevent autocatalytic degradation of YME1L1<sup>R149W</sup> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Our results unambiguously demonstrate that the precursor form of YME1L1<sup>R149W</sup> assembles into high molecular weight complexes. As we also observe low amounts of mature YME1L1<sup>R149W</sup> in patient fibroblasts (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>), the residual YME1L1<sup>R149W</sup> activity in these cells may result either from this population or from assembled YME1L1<sup>R149W</sup> precursor forms. We have now clearly stated these possibilities in the manuscript.</p><p><italic>The mechanism of YME1L<sup>R149W</sup> degradation is not clear. It's not clear if YME1L<sup>R149W</sup> is targeted to mitochondria efficiently in the first place or if it is degraded prior to entering mitochondria by other proteases (e.g., the proteasome). More experiments related to this point would be very helpful in further demonstrating exactly how this mutation influences YME1L activity in patient cells.</italic> </p><p>We have directly examined mitochondrial targeting of YME1L1<sup>R149W</sup> by immunofluorescence microscopy in <italic>YME1L1</italic><sup>-/-</sup> HeLa cells overexpressing YME1L1<sup>R149W</sup>. As shown now in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, the disease- associated mutation does not affect sorting of YME1L1 to mitochondria.</p><p>Moreover, we examined whether inhibition of the proteasome affects the accumulation of YME1L1<sup>R149W</sup>, but did not observe significant changes or stabilization in the levels of YME1L1<sup>R149W</sup> in cells treated with the proteasomal inhibitor MG132 (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). These results indicate that YME1L1<sup>R149W</sup> is not degraded by the proteasome prior to mitochondrial import. Rather, the mutant protein is degraded upon import into mitochondria in an autocatalytic fashion (<xref ref-type="fig" rid="fig3">Figure 3A</xref>).</p></body></sub-article></article>